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In 1996 the NHS Executive’s Pharmaceutical and Optical Branch invited health authority 
bids to carry out pilots testing some form of extended role for community pharmacy. In 1997 
it funded twelve pilots. Six of these were repeat and/or instalment dispensing schemes and 




These initiatives have to be set against the background of present changes in the NHS. In 
particular, in terms of the development away from a health service based on secondary care to 
one based more on primary care (Hassell et al., 1998, p. 5). Debates about the way 
community pharmacy should develop took place as long ago as 1971 when the then 
Pharmaceutical Society suggested that pharmacists should move towards a more patient-
oriented and clinical role (Eaton and Webb, 1979, p. 74). However, in recent years these 
debates have been sharpened. The 1986 Nuffield Report and the 1996 White Paper, Choice 
and Opportunity: Primary Care in the Future, emphasised the need for community 
pharmacists to become more involved in the Primary Health Care Team (PHCT). The new 
1997 White Paper, The New NHS, signals further changes in primary care by giving 
professionals who make prescribing and referring decisions more financial and clinical 
responsibility. This development could offer community pharmacists further opportunity to 
integrate more into the PHCT (Ruston et al., 1998, p. 2). 
 The 1996 White Paper advocated the development of community pharmacy in a way 
that would lead to a better use of prescribed medicines; wider recognition of pharmacists as 
the first port of call for minor ailments; health promotion and the provision of advice on 
medicines to other health care professionals. Having identified legal barriers to these 
developments, it proposed legislation that would give health authorities greater flexibility 
over the purchase of community pharmacy services and to enable NHS community 
pharmacists to apply to provide services from a local or neighbouring health authority (DoH, 
1996, pp. 9-10). The 1997 White Paper said that pharmacists would ‘need to be drawn in [to 
the PCGs] to contribute as appropriate to the planning and provision of services’ (DoH, 1997, 
p. 9/13). Although the Department of Health did not include pharmacists as members of the 
boards, some health authorities are approaching pharmacists to do specific tasks and, in some 
cases, have included them on the boards (Livingstone, 1998, pp. 161-2).  
The pilots have also to be understood in terms of developments within community 
pharmacy. In particular, there has been a significant shift away from people working in small 
independent pharmacies to multiples or supermarket pharmacies. Employee pharmacists now 
outnumber independent contractors, challenging the nature of service traditionally provided 
by pharmacists (Magirr, 1995, p. 876). There has also been a growing trend towards 
pharmacists working in health centres alongside GPs and dentists and chiropodists (Harding 
and Taylor, 1990, p. 464). These changes have led to some sense of insecurity, particularly 
amongst independent proprietors. For example, two Local Pharmaceutical Committees 
(LPCs) in London told a Government-sponsored review of London’s health services that the 
Department of Health was not providing enough backing to independents and that ‘pharmacy 
owners…have to live under a constant threat of possible relocation of neighbouring surgeries 
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into health centres where there is always an auction for the highest rent-paying pharmacy 
tenant’.1 Independent proprietors also regard the Government’s recent support for the 
abolition of Retail Price Maintenance for pharmacy within the Competition Bill as a threat to 
their livelihood. 
Finally, a large body of research has shown the negative consequences that arise when 
patients’ medication is not properly managed. According to a recent report by the National 
Pharmaceutical Association (NPA), studies have found that a significant proportion of 
hospital admissions stemmed from poor adherence to medication. They have also shown that 
some patients discharged from hospitals have not been able to maintain the prescribed 
regimen, and that patients on complex regimens are particularly vulnerable to poor 
adherence. In terms of drug wastage, one study on residual medicines in private households 
showed that 8% of the medicines were regarded either as ‘finished’ or ‘never used’ (NPA, 
1998, pp. 8-9). The Royal Pharmaceutical Society (RPS) also addressed the question of 
patient adherence in an important report called From Adherence to Concordance (1997). The 
RPS and the NPA are therefore committed to the need for pharmacy to adapt to a changing 
environment. The RPS initiated Pharmacy in a New Age (PIANA) which envisages 
developing community pharmacists’ involvement in the management of medicines; the 
management of long-term conditions; the promotion and support of healthy lifestyles and 
advice and support for other healthcare professionals.  
These practical developments have been reflected in the growth of pharmacy practice 
research (PPR) over the last fifteen years or so, marked by a variety of significant 
developments such as the RPS’s establishment of the College of Pharmacy Practice in 1981; 
the 1986 Nuffield Committee of Inquiry into Pharmacy, the 1987 Government White Paper 
Promoting Better Health and the formation of a number of pharmacy practice units in 
universities (Mays, 1994, pp. 9-11). However, the need to justify extending community 
pharmacy’s role was an important aspect of PPR. Moreover, it has suffered from limited 
input from researchers outside pharmacy and there has been evidence of bias resulting from 
pharmacists, in some cases, both carrying out projects and doing their own evaluations 
(Mays, 1994, pp. 2-3). Within this growing body of work, few attempts have been made to 
think about pharmacy in the context of wider health services research (Mays, 1994, pp. 16-7). 
 
The Pilot Projects 
In the following we provide a brief description of the twelve pilots funded by the Department 
of Health. Some of these projects have not yet finished. The classifications ‘RDS’ and ‘EAS’ 
have been used for simplicity. ‘RDS’ includes repeat and instalment dispensing schemes. 
‘EAS’ includes adherence and pharmaceutical care schemes. We have specified the type of 
project more precisely in the summary boxes at the start of each case outline. 
 
REPEAT AND/OR INSTALMENT DISPENSING SCHEMES  
 
Repeat Dispensing Scheme 1 (RDS 1) developed an instalment dispensing scheme to test its 
acceptability from the point of view of the pharmacists, doctors and patients and workload 
implications; to test a new form of remuneration for pharmacists; to evaluate the impact of 
the service on patient adherence. Participating GPs were responsible for patient recruitment. 
The study targeted patients suffering from TB, drug misuse, depression and the elderly or 
confused with a known history of non-adherence. The assessments took place in the 
pharmacy. 
 
Repeat Dispensing Scheme 2 (RDS 2) aimed to identify the benefits of a pharmacy 
controlled repeat and instalment dispensing service through an examination of its effect on 
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GP workload, the potential for making savings in drug costs, general acceptability from the 
point of view of the pharmacists, doctors and patients, and to test the feasibility of such a 
scheme in an area with a relatively high proportion of prescription charge payers. It targeted 
mixed chronic patients and the assessment was mainly pharmacy-based although there were 
some home-based assessments with housebound patients. 
 
Repeat Dispensing Scheme 3 (RDS 3) recruited patients stabilised on long-term medication 
through GP practices. It aimed to identify the acceptability of a repeat dispensing scheme for 
patients, pharmacists and doctors as well as to consider whether such a service could improve 
patient care, in terms of adherence and assessment of side-effects, and impact on drug costs. 
It targeted mixed chronic patients and the assessments were pharmacy-based. 
 
Repeat Dispensing Scheme 4 (RDS 4) carried out the largest of the repeat dispensing 
schemes, covering four localities. By testing slightly different services in each of these areas, 
it aimed to examine how different repeat dispensing schemes might affect repeat prescribing 
costs and patients’ quality of life, as well as to compare different remuneration systems for 
pharmacists and the effect of patients’ versus pharmacists’ retention of subsequent 
instalments of initial prescriptions. It targeted mixed chronic patients and the assessments are 
pharmacy-based. 
 
Repeat Dispensing Scheme 5 (RDS 5) designed a repeat dispensing scheme that aimed to 
identify appropriate patient groups, to evaluate the benefits from the point of view of doctors, 
pharmacists and patients, to identify barriers and constraints to the implementation of a repeat 
dispensing practice and to make recommendations about remuneration for pharmacists. It 
targeted mixed chronic patients and the assessments were carried out in the pharmacy. 
 
Repeat Dispensing Scheme 6 (RDS 6) is piloting a scheme aimed specifically at patients 
suffering from depression. In the light of evidence that many patients do not reach therapeutic 
level in their drug therapy, it aims to consider whether pharmacists can help patients to make 
optimal use of anti-depressant drugs. The community pharmacists will dispense the drugs in 
monthly instalments, reviewing the patient for adherence and side effects at each dispensing. 
The evaluation will look at the scheme’s impact on health outcomes, drug costs, general 
acceptability and feasibility. The assessments will take place in the pharmacy; although 
participating pharmacists will have to have a private consultation area. 
 
EXTENDED ADHERENCE PROJECTS 
 
Extended Adherence Scheme 1 (EAS 1) ran a pilot project that aimed to see whether 
pharmacists could identify patients who needed adherence support; to establish reasons for 
poor adherence; to raise awareness of adherence difficulties amongst health care workers; to 
identify appropriate patient groups who needed help with adherence; to identify an 
appropriate patient referral system; to improve patients’ use and understanding of their 
medicines and to consider the scheme’s potential to prevent drug wastage. It targeted mixed 
chronic patients and the assessments took place at home. 
 
Extended Adherence Scheme 2 (EAS 2) designed an extended adherence project that 
focused on patients suffering from hypertension. It aimed to examine whether regular 
pharmacist reviews of patients’ medication taking and side effects could improve patients’ 
adherence and blood pressure control. It also aimed to look at the potential benefits of such a 
scheme for pharmacists and doctors. The assessments took place in the pharmacy.  
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Extended Adherence Scheme 3 (EAS 3) ran a pilot study that explored how community 
pharmacists, in co-operation with GPs, could contribute to the care of patients with stable 
angina. It aimed to analyse changes in patient management resulting from the delivery of six 
evidence-based interventions; to determine how pharmacist-run review clinics could affect 
patients’ quality of life and to explore the pharmacist, doctors’ and patients’ views on the 
review clinics.  
 
Extended Adherence Scheme 4 (EAS 4) ran an extended adherence project where the 
pharmacist assessment took place in patients’ homes. It targeted elderly and confused 
patients. It aimed to develop ways of identifying patients who are at risk of non-adherence 
through the Patient Medication Record (PMR); to implement an adherence management 
action plan for these patients; to equip the participating pharmacists with the necessary skills; 
to evaluate the potential costs and benefits of such a service for the patients, professionals and 
the NHS.  
 
Extended Adherence Scheme 5 (EAS 5) is piloting a service based on a mixture of pharmacy 
and domiciliary-based visits by pharmacists. It is targeting elderly patients with mental health 
difficulties. The pharmacists work in liaison with existing mental health care teams to assess 
patients’ needs.  
 
Extended Adherence Scheme 6 (EAS 6) is piloting a pharmaceutical care service in 
Sheffield involving twelve pharmacists. The project aims to investigate the impact of a 
community pharmacist based adherence/pharmaceutical care support service for heart failure 
patients given that adherence to medication is likely to reduce risk of hospitalisation and 
improve quality of life. Having reviewed the patients’ adherence, the pharmacists submit a 
care plan to the GPs for approval. The aim of the study is not to look at health outcomes but 
to assess the acceptability of such a service for pharmacists, patients and doctors. 
 
Two goals underlie all these projects in so far as they aim to find ways of improving patients’ 
use of their medications and to discover ways of helping to reduce the NHS drugs bill 
(although this second goal was more explicit in four of the repeat dispensing schemes). 
However, their distinctive features are important in considering what aspects of extended 
roles are feasible; namely where the reviews took place; how patients were recruited; types of 
patients targeted; the use of specially designed prescriptions; whether patients had freedom of 
choice of pharmacy (in the repeat dispensing pilots); kinds of remuneration systems for the 





2. CHSS CENTRAL EVALUATION 
 
The Department of Health appointed a central evaluation team at the Centre for Health 
Services Studies (CHSS) at the University of Kent to carry out an overall evaluation of all of 
these pilot projects. Our aim in this project was two-fold.  First, to provide methodological 
support to the local sites piloting community pharmacy extended role projects and second, to 
provide an over-all evaluation of the pilot projects. 
 
Objective One: Support 
 
The study was divided into two stages.  In the support stage we liaised with sites and 
provided them with academic support about the projects’ evaluation, including advice on 
setting up the projects, data collection tools and data analysis.  We concentrated our efforts 
mainly on projects that had no local links with academic departments, including RDS 1, EAS 
1, RDS 3 and EAS 5. We provided EAS 4 and RDS 2 Health Authorities with moderate 
support. A local university worked with EAS 4 Health Authority and a hospital academic unit 
provided RDS 2 HA with academic support. Our support role was minimal in the sites that 
had strong academic support through links with local universities, namely, EAS 2, EAS 3, 
EAS 6, RDS 4 RDS 5, RDS 6. 
 Starting in June 1997 members of the central evaluation team made a number of visits 
to the individual sites to introduce themselves, assess the sites’ needs and provide further 
support if and when needed. We visited the sites with the lowest level of academic support 
first and then started to make visits to those needing less academic input from the CHSS. 
Team members gave advice to the sites on setting-up, appropriate data collection tools, 
analysis and, especially for those sites without local academic links, moral support and 
encouragement for project managers (see table 2.1). 
 The CHSS team carefully followed each site’s progress, keeping a log of any 
developments or changes in procedure and implementation problems. The key issues that 
arose included difficulties in patient recruitment and GP co-operation. We shall explore these 
questions in further detail in the case studies. 
In their evaluations, the majority of the sites used questionnaires rather than focus 
groups or in-depth interviews to ascertain the pilot’s acceptability to the patients, pharmacists 
and doctors. The team provided support on an individual basis, both face-to-face and by 
telephone. The team’s initial input primarily centred on questionnaire design. We received 
draft questionnaires from all of the sites and provided suggestions for revision in writing 
where appropriate or necessary. We provided advice on sampling in relation to patients, 
patient inclusion criteria and the appropriateness of control groups. The team also provided a 
framework for analysing cost data for the four repeat dispensing sites. 
EAS 1  The central evaluation team advised on the design of questionnaires for 
patients, referrers and carers. We recommended on the minimum sample size of patients to be 
interviewed, and modified this in the light of a shortfall in recruitment. We discussed 
recruitment blocks and ways of getting around them. We successfully liaised with the site in 
order to overcome initial concerns about our access to patients. We helped the site with data 
input and analysis and recommended the use of an independent researcher to help with these. 
We commented on the draft final report.  
The project was based on a qualitative analysis of interview data and provided some 
descriptive statistics on the project’s acceptability to the key stakeholders; changes in 
adherence and health outcomes; storage and hoarding and drug wastage. Data sources 
included a referral form; assessment form; care plan; follow-up assessment form; care plan 
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review; medicines disposal forms; GP recommendation form; GP reply form; patient 
questionnaire; referrer/carer questionnaire; pharmacist questionnaire.  
RDS 1  The central evaluation team provided advice on questionnaire design for the 
pharmacists, GPs and patients. We discussed the difficulties of getting a high response rate 
for the patient groups concerned and recommended some face-to-face interviews. We 
suggested simplifying GP and pharmacist logs to make them more manageable. The team met 
up with the steering group to discuss recruitment difficulties and recommended providing an 
incentive for GPs to participate and to liaise more with practice managers. We reviewed the 
draft final report and made suggestions for its revision.  
The evaluation focused on four main areas including, the service’s general 
acceptability; its impact on patient health and adherence; value added by pharmacists and 
costs. Data sources included: prescriptions; post-intervention questionnaires for GPs and 
pharmacists; pre and post-intervention patient questionnaires; GPs’ logs of patient contacts 
and details; pharmacist logs on patient details, dispensing, interactions with patients; informal 
conversations with GPs and pharmacists; patient medical records and pharmacy dispensing 
records. Data were analysed using Access database and Excel spreadsheet. Because the 
number of patients enrolled was low, the project manager did not perform any statistical 
analyses, although she did provide some descriptive statistics. 
RDS 3 The central evaluation team made comments on questionnaire design for the 
patients, GPs and pharmacists (pre and post-intervention). We advised on the set up of a 
database and cost analysis. The project manager carried out an analysis of general 
acceptability for the pharmacists, GPs and patients. Data sources included: pre and post-
intervention questionnaires for the pharmacists, doctors and patients; patient intervention 
forms (completed by pharmacists) with information on patients’ understanding of and 
adherence to their medicines and record of action taken (if any) by the pharmacist; GP 
referral forms; The project manager carried out a quantitative analysis of savings in drugs 
costs using Excel 3.11 with data on patient’s gender, age group, exemption status; GP ID 
code and surgery post-code; drugs prescribed (BNF category) and dose prescribed; date of 
dispensing; quantities dispensed and cost of dispensed drugs from PPA listings. 
RDS 2 The central evaluation team provided comments on the draft questionnaires for 
the patients. We liaised with the site over progress and helped it to get local ethical approval 
for the central team to carry out a joint focus group with patients. We advised on price 
sources to be used to measure changes in drug costs (BNF) and on databases.  The central 
evaluation team is also inputting cost data into Excel database and analysing them according 
to the framework provided for the repeat dispensing schemes’ drug cost analysis. 
Data sources included: prescriptions; pharmacist-held prescription event record (e.g. 
recording any changes in medications, supply of medicines, problems identified and action 
taken); pharmaceutical care record (to document an events/communication that occurred 
outside pharmacist review and collection of prescription); referral letter from pharmacists to 
GPs; repeat prescription request form; pre-study patient questionnaire (to assess attitude to 
adherence to medicine; information needs; satisfaction with current repeat prescribing 
service); post-study patient questionnaire (to assess patients’ views on pharmacists’ role, 
extent to which service met their needs, and benefits or otherwise of the scheme). 
EAS 5 The original plan for a local university department to support this pilot did not 
go ahead. The CHSS team therefore became the sole academic link. At the first visit, 
members of the central evaluation team raised queries about the patient sample size; patient 
inclusion/exclusion criteria and the nature of the pharmacists’ intervention. At subsequent 
meetings we provided the project manager with advice on questionnaire design; patient entry 
criteria; patient randomisation into control and intervention groups; the need for screening out 
patients too confused to take part; ways of linking patients with pharmacies; pharmacist 
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recruitment; pharmacist remuneration and the use of health outcome scales. We supplied the 
project manager with a simple test of mental function (Abbreviated Mental Test); examples 
of adherence questions and patient consent forms. We also advised that cost issues would 
mainly turn on matters such as patient adherence for this particular type of project. However, 
we suggested that the project manager get a record of what was actually supplied (brand and 
quantity) for a costing to be carried out at the end of the project. Data sources include patient 
assessment questionnaire; domiciliary pharmaceutical assessment; domiciliary 
pharmaceutical care plan; pharmacist intervention form; Health of the Nation Outcome 
Scales (HONOS).    
 
Table 2.1 COMMUNITY PHARMACY WIDER ROLE PROJECTS 































































































































































EAS 4 The central evaluation team’s role was minimal in this project. At the initial 
stages we commented on the questionnaire design and then liaised over the site’s progress. 
Data sources include: patient questionnaire administered by the pharmacist at the first 
and follow-up visit with information on collection timing in previous three months, 
understanding of medicines, use of medicines and inhalers, adherence and pharmacist action 
plan; quality of life questionnaire with data on mobility, self-care, usual activity, 
pain/discomfort and anxiety/depression; consent form for the disposal of unwanted 
medicines. 
RDS 4 The central evaluation team did not need to provide any methodological 
support for this project. A university department is carrying out a qualitative evaluation of the 
pilots. Researchers in there are collecting data on the pilots’ general acceptability to the 
patients, GPs (and other practice staff) and pharmacists and on changes in GP/pharmacist 
workload. Data sources include GP questionnaires; practice manager questionnaires and 
pharmacist questionnaires. They are also carrying out telephone interviews with a small 
sample of patients from each health authority area to provide in-depth information on patient 
experiences. The sample populations for the questionnaires include all GPs and practice 
managers in each practice and any other member of practice staff who had been closely 
involved with the study and community pharmacies who received study prescriptions for over 
10 patients per month. Data from the questionnaires are being entered into the statistical 
package SPSS and frequencies of responses recorded. Qualitative information from all 
questionnaires is being coded and analysed. 
Another university department is carrying out a quantitative evaluation. Data sources 
include: GP registers (newly sampled patients; patients ineligible for sampling; extra contacts 
with study patients); pharmacy registers (prescription forms for study patients; extra contact 
forms for study patients); patient questionnaire 1 (information about how patients get their 
repeat prescriptions and health); patient satisfaction questionnaires (information on 
acceptability, preferences and outcomes). The evaluators are collecting data on patient 
satisfaction with a sub-sample of patients per GP practice by postal questionnaire and a small 
number of qualitative patient questionnaires. SF-36 and Euro-Quol are being used to measure 
patients’ health status before, during and after the repeat dispensing schemes. 
EAS 3 The central evaluation team did not provide any methodological support for 
this project. The Health Authority commissioned a local university department to carry out an 
independent evaluation. The Department did a qualitative analysis of stakeholders’ views of 
the service and a quantitative analysis of health outcomes. 
Data sources included: Seattle Angina Questionnaire (SAQ) self-administered by 
patients at the first and last pharmacist review to provide information on health outcomes; 
Pharmacist records including general information on patient demographics, GP and 
pharmacist identity, angina grade, allergies and other medical conditions; information on 
activity status; weight and diet; smoking; cholesterol levels; aspirin therapy; Beta-blocker 
therapy and any other information; face-to-face interviews with pharmacists at the start and 
end of the pilot study; face-to-face interviews with a sample of GPs at the end of the study; 
in-depth interviews with group of 5 patients who took part in the clinics; telephone interviews 
with a group of 50 patients (selected by random to obtain a one in three sample); telephone 
interviews with a random sample (one in three) of non-attenders.  
EAS 2  had a local academic link and the CHSS team therefore provided a low level 
of support to this site. At a meeting in November 1997, the central evaluation team discussed 
the need to find out whether there was a clinical effectiveness programme relating to 
hypertension taking place within primary care that could affect the project’s outcome; the 
discrepancy between the number of patients who initially agreed to take part in the study and 
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the number who actually completed the initial questionnaire and consent form and the need to 
look at non-responders’ characteristics. The team also discussed access to data relating 
pharmacist characteristics to patient outcomes and cost data. 
Patient outcomes are being measured by data provided in the patient satisfaction 
questionnaires completed at the start of the study and at the 8-month follow up point; 
adherence data collected from intervention and control group patients at the start of the study 
and at the 6-month follow-up point through a semi-structured interview using a standard 
question series and blood pressure measurements obtained from the GP patient medical 
records for all patients. Patients who had low scores on the adherence questions are being 
cross-referenced with a) pharmacist profile (location; ownership; age; private counselling 
areas) and b) patient profile (age; sex; time since diagnosis; treatment and c) deprivation 
(through postcode analysis). Numbers of requests for information on health condition and 
requests for information on medication are being cross-referenced with a) adherence scores, 
b) pharmacist profiles and c) patient profiles. Data sources included patient profile; 
pharmacist profile; pre-study patient questionnaires; patient satisfaction questionnaires; 
pharmacist intervention form; GP response questionnaire; GP records (for blood pressure 
readings). Counts are being made of patients experiencing side effects; pharmacist responses 
(proportion of responders giving advice on information about health condition/medication; 
proportion referring patients to the GP and the proportion of GP referrals that made 
recommendations and the proportion that recorded follow-up). 
RDS 5 The central evaluation team did not provide any methodological advice to this 
project. We reviewed the data collection tools and recorded the project’s progress and the 
revised protocol that meant that the pharmacist would be remunerated on a patient-centred 
basis rather than item driven. In its evaluation, Birmingham Health Authority is carrying out 
both qualitative analysis of acceptability from the point of view of the patients, pharmacists 
and GPs and quantitative analysis of changes in drug costs as a result of the intervention. 
Data sources include a specially designed repeat prescription form; referral forms (pharmacist 
to GP); patient recruitment postal questionnaires; PMRs; post-intervention survey of patient 
satisfaction; focus groups with GPs and pharmacists. 
EAS 6 commissioned an institute at a local university to carry out the evaluation of 
this pilot. The central evaluation team followed the project’s progress and noted changes in 
its objectives. At the outset the aim was to carry out a randomised control trial of a 
pharmacist-led intervention to provide enhanced after-care to heart failure patients after 
discharge from hospital. There was going to be a baseline measurement of the patients’ 
quality of life followed by assessments at one and three months using a validated 
questionnaire. The central evaluation team held a meeting with the IHA evaluators and noted 
that the project had changed from a randomised control trial to an exploratory “action 
research” project to look at service quality and problems from the patients, pharmacists’ and 
GPs’ standpoints. The project will no longer be looking at clinical outcomes.  
Having suffered some delays with the ethics committee and recruitment blocks, the 
project is progressing. The evaluators have carried out a preliminary focus group with health 
professionals and a one-to-one interview with a hospital consultant with the aim of agreeing 
roles and priorities in the care of heart failure patients and how the pharmacy service would 
fit in with other agencies. To date, hospital and community pharmacists have recruited 
nineteen patients. The evaluators are going to explore the participants’ views on the service 
through focus group discussions with the professionals and, possibly, patient questionnaires. 
RDS 6 This pilot’s need for methodological advice from the central evaluation team 
was low. A local university and consultancy are providing support and the lead researcher has 
a strong previous background in research of the type. There have been delays in the pilot’s 
start, partly because of difficulties concerning ethical approval. The study is based on both 
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intervention and control groups of patients on treatment for depression and recruited into the 
project by the GPs. The evaluation aims to measure changes in clinical outcome; drug 
treatment costs; prevention of waste; impact on the community pharmacists and GPs; benefits 
for patients and feasibility beyond the pilot stage. Data collection tools include a diary for 
each patient including information on patient details; time spent by the pharmacist; number of 
visits made to the pharmacy; adherence to treatment; medication side effects; referrals back 
to the GP; changes in treatment; HAD scale (Hospital Anxiety and Depression Scale is a 14 
item self report which is sensitive to changes in anxiety and depression); the number of 
patients dropping out of treatment; referrals and admissions to hospitals. Pharmacy held 
PMRs will also be used to verify information in the diaries and to record drug costs; GP held 
patient notes will also be used to provide information on the number of GP consultations with 
the patient during the intervention period. Interviews will be held with participants from both 
active and control groups. 
 
Objective Two: Overall Evaluation 
 
Our aim in the second part of our project was not to evaluate each site as such but to draw out 
common themes cutting across all the projects and to disentangle what was unique to each 
project and what was general to them. An overall evaluation also offered the opportunity to 
compare models and to draw out which aspects of the services worked well and which ones 
did not, such as the use of different types of prescription or remuneration levels for the 
pharmacists. This project examines six key themes:   
 
 General acceptability  
 
 Feasibility  
 
 Generalisability  
 
 Impact on adherence  
 
 Freedom of choice of pharmacy 
 





We had some difficulties defining the central evaluation team’s relationship with the 
individual sites concerning first, the degree of authority it had and second, the question of 
sharing data.  Although most of the sites had a very clear idea of our support role and some of 
them found it a very valuable resource, the majority (initially at least) did not seem to be very 
clear about our evaluative role. Some of the sites were concerned about a conflict of 
academic interests and ethical issues surrounding access to patients. 
 There were also issues relating to comparability. Each of these sites had its own 
particular local rationale and local demographics. For example, the EAS 3 project reflected 
the health authority’s aim to target action on three main diseases in the area, cardiovascular 
disease being one of them. The target patient group in the RDS 1 pilot reflected health 
problems characteristic of inner cities. The sites used different ways of measuring adherence 
too. For example, some sites used prescription pick-up dates and others asked the patients to 
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report on whether their adherence to their medicines has improved as a result of the 
pharmacist interventions. They also collected data on drug costs in different ways. Some 
projects wanted to see whether patients took fewer drugs in the intervention phase than in the 
pre-intervention stage. Others considered whether the pharmacists’ interventions could 
reduce drug wastage through an estimate of how many medicines they took from people’s 
homes. Remuneration for the pharmacists and the doctors also varied across sites. The RDS 4 





The CHSS evaluation was divided into two parts. The first consisted of a qualitative analysis 
of the schemes’ general acceptability. It is important to link research methods with the kinds 
of questions being addressed in any project. Our interest here was in exploring stakeholders’ 
views on a particular service and what they thought was successful or not so successful about 
them. Thus the approach adopted was based on stakeholders’ perspectives (See Ovretveit, 
1998, p. 51), from which follows a qualitative method of data collection. Qualitative research 
refers to the use of methods for data collection that pay attention to actors’ subjective 
perceptions (Faltermaier, 1997, pp. 357). It does not provide numerical answers to questions. 
Rather, it aims to illuminate people’s experiences and views through the use of in-depth 
interviews, focus group discussions, observation and case studies (Pope and Mays, 1995, pp. 
43-4).  
 We were interested in the perceptions of people who had a stake in the new services 
and who would influence their possible implementation in the future. In this case, this meant 
the service providers (the community pharmacists); the service recipients (the patients) and 
health care professionals involved in the pilots (GPs). GPs and pharmacists were the main 
referral sources. In some cases, there were other sources, such as carers or nurses. However, 
we focused on the main referrers for resource reasons and consistency. We were also 
interested in the attitudes of other actors who took part in the projects’ set-up, namely, the 
project managers and Local Medical Committee (LMC) and Local Pharmaceutical 
Committee (LPC) representatives (See figure 1).  
 Pilot interviews were carried out with local GPs in December 1997 and with 
pharmacists based in EAS 1 in February 1998. We used these to finalise our interview 
schedules and began collecting data in April 1998. We could only start this phase after the 
local sites’ interventions and own interviews had been carried out. We interviewed the 
professional stakeholders by telephone and carried out focus group discussions with patients 
organised jointly with the local project manager in each site. Resource considerations meant 
that it was possible to do one focus group in each locality. We had to revise the scope of our 
data collection with respect to patients in the light of some health authorities’ and project 
managers’ concerns. For example, there were worries about the ethical issues of contacting 
patients for contacting patients further and there were concerns that elderly patients attending 
a focus group several months after the intervention would not be appropriate. Other reasons 
were more practical, with patients seeming not to want to take part in the focus group and not 




A purposive sample of the professional stakeholders was selected to ensure that the study 
included pharmacists and GPs from as broad a range as possible. We selected the pharmacists 
primarily according to whether they worked in independents or multiples, whether they were 
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in rural or urban locations, and the extent of their involvement in the scheme. GPs were 
chosen according to practice size, whether they were in urban or rural locations and the extent 
of their involvement in the scheme. We also interviewed six out of seven project managers 
(whose pilots have been included in this report) and nine representatives from various 
relevant LPCs and LMCs. In selecting the quota for the sample we made a judgement about 
how many interviews it would be feasible to do given the time frame of our study and 
resources. We then proceeded to try and meet this target (six pharmacists and four GPs) in 
each pilot.  
 We liaised with the local project managers over setting up a focus group and they 
dealt with patient recruitment. The project manager either directly contacted (or indirectly 
through a practice manager) twelve patients in the hope that eight would agree to attend. In so 
far as the groups only included patients who consented to come, they were self-selected, 
raising the question of possible bias in their responses. This was unavoidable and means that 
the patients’ responses need to be treated with caution.  
 















Number of GP 
practices 
 































































































Telephone Interviews and Focus Groups 
 
We carried out semi-structured telephone interviews with a sample of pharmacists and GPs 
who participated in the scheme. There have been some concerns raised about the validity of 
these interviews compared with face-to-face ones. In terms of quality of data, the concern has 
centred on whether telephone interviews yield valid data, especially when they are about 
sensitive health-related topics. Research has produced inconsistent findings. Some of it has 
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indicated that telephone interviews are as useful as face-to-face ones. Other research has 
shown that interviewees tend to give shorter responses to open-ended questions and that the 
telephone interview proceeds faster than that face-to-face interviews. The obvious advantage 
however, is that such interviews facilitate cheap and fast access to geographically disparate 
groups (Thomas and Purdon, 1994, pp. 1-6). In this study, personal health issues were not 
explored and we found little evidence of respondents’ reluctance to answer questions fully.  
 We used focus groups as a way of accessing patients’ views of the services because 
they are a fast and cost effective way of interviewing a number of people. Like telephone 
interviews, there has been some debate about the validity of obtaining data through focus 
group interviews and they do have some limitations. In particular, recruitment tends to be 
based on convenience rather than representation and the group dynamics may affect 
individual opinions. However, they are a very useful way of doing exploratory research and 
their open format provides opportunities for gathering rich data (Stewart, 1990, pp. 16-7). 
 The professionals’ telephone interview schedule consisted of open ended questions 
with prompts to be used if necessary and covering the following issues: reasons for taking 
part in the pilot; pilot’s impact on job satisfaction/workload; use of other staff (pharmacy and 
GP practice); patients’ views; pilot’s impact on patients’ adherence; pilot’s impact on drug 
costs; pharmacists’ role in the PHCT and attitudes towards pharmacists extending their roles 
in the areas identified by PIANA. The patient focus group schedule also consisted of open-
ended questions with prompts. It centred on what the patients’ pharmacy service was like 
before the pilot; what was different about the new pharmacy service; patients’ relationship 
with the pharmacists; confidence in pharmacists’ expertise; the new service’s convenience; 
privacy; whether they thought it had helped them in taking their medications and the patients’ 
idea of their ideal pharmacy service. 
 







Community pharmacists 38 
GPs 25 
Project managers 6 
LPC representatives 5 
LMC representatives 4 
Patient focus groups 3 
 
 
Sites’ Final Reports 
 
The sites’ own final reports have also informed our evaluation as secondary data sources. We 
have received final reports from EAS 1, EAS 3 and RDS 3 and draft reports from RDS 1 and 




The telephone interviews were transcribed verbatim and the transcripts were analysed in 
terms of the key concepts outlined above, namely, general acceptability; feasibility; 
generalisability; adherence; costs and freedom of choice of pharmacy. We looked for 
recurring themes and selected illustrative quotations of recurring themes. We indicated in the 
text where views that were expressed were not generally held.  
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In the focus group discussions a member of the central evaluation team moderated 
and the local project manager was present. We explored the ways patients had received their 
medications in the past, how the new service differed from their previous experience, and 
whether they found the service acceptable. We transcribed the discussions verbatim and 
analysed the transcripts in terms of recurring themes that came up in response to these 
questions about the pilots. 
Our analysis of general acceptability (for the professionals) turned on issues 
concerning workload, level of training, job satisfaction, and perceptions of appropriate roles 
for pharmacists. For the patients, general acceptability referred to their confidence in the 
pharmacists’ skills, extent of contact with the pharmacists; the issue of GP/pharmacist roles; 
privacy; convenience; perceived improvement in use of medication and health. Our analysis 
of feasibility looked at stakeholders’ views on whether the scheme worked in terms of 
workload, remuneration, and patient recruitment and prescription type where appropriate. 
Our analysis of generalisability centred on stakeholders’ views on whether the projects could 
be rolled out nationally or whether they were more appropriate in some localities than others, 
especially in terms of particular local health needs. Our analysis of adherence was based on 
the stakeholders’ perceptions of whether patient adherence had changed as a result of the 
interventions. By adherence we mean taking drugs in the way prescribed. We supplemented 
these findings with the health authorities’ own findings, noting the way they collected 
information on adherence. Some of the sites considered it in terms of patient pick-up rates for 
their prescriptions. Others looked at it according to the results of a medicine cognisance test 
carried out at each intervention to see whether there had been any improvement in patient 
understanding.  
Our analysis of freedom of choice of pharmacy was based on stakeholders’ perceptions 
of the benefits or otherwise of patients regularly using the same pharmacy and their views on 
registration, voluntary or obligatory. Patient freedom to choose the dispensing pharmacy did 
not apply in all of the sites. The question was particularly relevant to the repeat dispensing 
projects where patients could only get subsequent supplies by going to the same pharmacy. 
However, where this issue was not specifically related to the particular scheme, we asked the 
interviewees for their views on the subject in principle. 
 
Costs Analysis  
 
In the cost analysis section we summarised the level of savings made in relation to non-
dispensed drug items for each of the pilot sites for which data were available.  We explored 
some of the variations in savings both within and across the studies, drawing comparisons 
wherever possible. In the analyses savings were measured in four different  ways, the results 
of which should be considered in combination. These four measures are:- 
 
 As a total saving  
 As a percentage of prescribed costs  
 Number of non-dispensed items 
 Average saving across these non-dispensed items 
 
These were estimated for each site over the entire six-month period and per instalment.  In 
addition, they were calculated separately in four subgroups, including: pharmacy type, drug 
category, pharmacy and GP practice. As an additional individual measure across the whole 
period, the average costs per prescription item was calculated based on the numbers of items 
prescribed and the total costs of items dispensed. 
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4. CASE STUDIES 
 
In this report we have first of all described the individual sites’ projects to provide an idea of 
their key characteristics and how they differ from each other. We then go on to provide an 
overall analysis in the results and discussion section. In this way, our general evaluation has 
been informed through a comparison of specific cases. In this report, we shall be looking at 
seven pilot projects. This includes repeat dispensing scheme types 1, 2, 3 and 4.1 and 
extended adherence schemes types 1, 2 and 3. RDS 4.1 is one of a number of pilots taking 
place under RDS 4. These are the sites where we carried out our own research. However, we 
are also including a brief description of RDS 5 because we are covering the cost analysis of 
this site in a separate section. 
 
REPEAT AND/OR INSTALMENT DISPENSING PILOTS 
 
 
REPEAT DISPENSING SCHEME TYPE 1 (RDS 1) 
PILOT’S MAIN CHARACTERISTICS 
 
Pilot type: Instalment dispensing 
Patient groups targeted: TB; mental health; drug addiction; elderly and 
confused 
Expected number of patients recruited: 150-200 
Actual number of patients recruited: 32 
Referral source (s): GPs 
Number of participating pharmacies: 19 
Pharmacist remuneration: £1.00 fee for each instalment dispensed and 
£1.00 fee for each observed consumption plus £10.00 fee on return of study 
documentation 
Pharmacist reviews’ location: Pharmacy 
Number of participating GPs: 34 GP practices 
GP remuneration: £25.00 per patient enrolled paid in two parts: on 
recruitment and on return of post-intervention documentation NB Introduced 
part way through the study 
 
RDS 1 aimed to develop a community pharmacy service where medicines were dispensed in 
instalments for defined patient groups. The pilot differed from the repeat dispensing schemes 
in that its purpose was to provide a prescription where the total quantity of the drug 
prescribed is dispensed in small amounts at a time (three instalments per week). It targeted 
patients with a known history of poor adherence that fell into four main groups: TB sufferers, 
patients with mental health problems, drug abusers and the elderly and confused. GPs in the 
RDS 1 locality selected the patients into the scheme according to the defined inclusion 
criteria.  Thirty-four GP practices and nineteen pharmacies took part in the scheme. Doctors 
were responsible for enrolling patients on to the scheme. The pharmacists got a fee of £10.00 
on receipt of documentation.  The PPA paid 94.1 pence of all instalments and the pharmacists 
had to claim a balance of 5.9 pence for every instalment from the RDS 1.   
 The project encountered some difficulties. In particular, patient recruitment was low. 
The manager and the steering group had anticipated recruiting around 150 to 200 patients, an 
informed estimate based on the number of GP surgeries running mental health and drug abuse 
clinics in the area and the two TB clinics. In the end, 32 patients were recruited. Out of these, 
there was a high number who were from a low socio-economic background. Many of them 
suffered from drug addiction problems or mental illness. No homeless or TB patients were 
recruited. 
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 This low recruitment could have stemmed from demographic factors. As an inner city 
area, RDS 1 has a high level of homelessness and mobility. The very mobility of these 
patients made them difficult to recruit, even though they were precisely the patients targeted. 
Another possible factor related to patient consent. Doctors found that a number of patients 
did not want to take part in the project. Again, this difficulty could have flowed from the type 
of patients who were targeted. Patients who abused the drugs prescribed to them did not want 
small quantities prescribed at a time or observed consumption. It is possible that people 
suffering from mental health problems disliked being singled out and were worried about 
being stigmatised. 
 There were two reasons why no TB patients were recruited on to the scheme. The 
manager had contacted two TB clinics in the area and one of them did not enrol patients for 
practical reasons. However, the other refused to co-operate because they had already 
established a protocol and prescribing nurse to deal with non-compliant TB sufferers. This 
was significant, because for community pharmacists to work effectively in this area there is a 
need for co-ordination with other health care workers and it casts doubt on the need for 
pharmacist intervention in this way if nurses could do it. 
 The project also suffered from a lack of GP co-operation. Initially, it targeted two 
practices from each of the six RDS 1 local areas in order to reflect the variety of practice 
types and geographic distribution. Later, it invited all the GP practices in the Health 
Authority area to take part. The lack of co-operation could have reflected the workload 
associated with having to recruit patients. The doctors had to carry out an in-depth review of 
patients in order to recruit and then to complete post-intervention documentation. 
 GPs’ lack of co-operation could have arisen because of the uncertainty surrounding 
remuneration. At first, the Health Authority did not provide the doctors with any financial 
incentive to take part in the scheme. It was only in response to low recruitment levels that the 
Health Authority offered the doctors remuneration. Doctors then got £25.00 per patient 
enrolled. This was paid in two parts: first, on recruitment and then after completion of the 
post-intervention documentation.  
 
*It should be noted that ongoing conversations with the project’s manger have informed 




REPEAT DISPENSING SCHEME TYPE 2 (RDS 2) 
PILOT’S MAIN CHARACTERISTICS 
 
Pilot type: Repeat and Instalment 
Patient groups targeted: Chronic 
Expected number of patients recruited: 200 
Actual number of patients recruited: 185 
Referral source (s): GP 
Number of participating pharmacists: 13 
Pharmacist remuneration: £30.00 fee for each patient who presented with 
a prescription 
Pharmacist reviews’ location: Mainly pharmacy-based, some domiciliary 
Number of participating GPs: 8 GP practices 
GP remuneration: £1000 to cover administration costs plus a printer 
 
RDS 2 piloted a pharmacist controlled repeat prescribing scheme (PCRPS) for patients 
receiving medication for chronic conditions.  The pilot had five main objectives:  
 
 to identify potential benefits to patients  
 to assess the service’s impact on GP workload  
 to identify potential savings in drug wastage  
 to assess its acceptability to patients   
 to test the feasibility of such a scheme in an area  
with a relatively high proportion of prescription payers. 
 
In this scheme the GPs selected the patients.  After obtaining the patients’ consent, they wrote 
a three-part prescription to be dispensed by the participating pharmacists.  The pharmacist 
dispensed the first part and arranged for the patient to collect the second instalment; he or she 
repeated this process at the second instalment and then, at the third dispensing the pharmacist 
carried out a medicine review and asked for a further three-part prescription from the GP 
incorporating any changes agreed with the doctor and the patient. Pharmacists were paid a fee 
of £30.00 for each patient in the scheme who presented with a prescription.  The fee covered 
the professional and management aspects of each three-month period and did not reflect the 
number of items on the form. 
 This project was a success in terms of patient recruitment. One hundred and eighty-
five patients were recruited, only just short of the 200 target. This could have stemmed from 
the simplicity of the referral process, with doctors being the only source of referral. The 
Health Authority’s Pharmaceutical Adviser also consulted with the GPs at the outset and the 
practices got quite a high financial reward: £1,000 per practice to cover administration costs 
plus a printer. Some of the GPs we interviewed mentioned that this had been an incentive to 
participate. However, one of the key aims of the project had been to do a comparison between 
patients who pay for the prescriptions and those who do not. In the end, only 8 patients who 
paid for their prescriptions took part. This might have been because it was difficult for people 
who worked to visit the pharmacies. Or it could have resulted from doctors’ perceptions 
about who needed the service most. Although the project manager asked them to recruit a 
broad range of patients, the GPs had considerable autonomy about who to recruit. 
 





REPEAT DISPENSING SCHEME TYPE 3 (RDS 3) 
PILOT’S MAIN CHARACTERISTICS 
 
Pilot type: Repeat dispensing 
Patient groups targeted: Stabilised on continuous therapy 
Expected number of patients recruited: 400 maximum 
Actual number of patients recruited: 242 
Referral source(s): Practice receptionists; Practice managers; GPs 
Number of participating pharmacies: 57 
Pharmacist remuneration: Drug tariff fee (94.6p) for each instalment item 
dispensed and £5.00 fee for each completed structured intervention 
questionnaire when patient presented for each instalment 
Pharmacist reviews’ location: Pharmacy 
Number of participating GPs: 7 practices 
GP remuneration: £200 retainer fee for each participating practice plus 
£25.00 fee per patient recruited 
 
This pilot aimed to investigate the feasibility of a community pharmacy-based repeat 
dispensing scheme from the pharmacists’, GPs’ and patients’ perspective. Its objectives 
included:- 
 
 an evaluation of the implications of the scheme for GP practices in terms of acceptability, 
benefits, convenience and time 
 an evaluation of the acceptability, benefits and convenience of the scheme for patients 
and its impact on patient adherence 
 an evaluation of the community pharmacy’s role in improving patient care (e.g. side 
effects/ adherence); workload and perceived benefits to professional role 
 identification of the impact of a pharmacy controlled repeat dispensing scheme on drug 
costs 
 
Seven GP practices took part in this project and it was open to all pharmacies in the health 
authority area. The GP practices were responsible for recruiting patients on to the scheme 
and, although there was some GP involvement in this, practice receptionists and managers 
did most of the patient enrolment. The patient inclusion criteria include patients identified as 
taking repeat medication for six months before the pilot’s recruitment phase; patients who 
would use a pharmacy within the health authority boundaries for the pilot’s duration; patients 
who had been registered with the GP practice for at least six months and who were willing to 
collect their repeat medication at approximately 28 day intervals. The pilot excluded patients 
who were under the age of 16; taking the oral contraceptive pill; patients needing surgical 
supplies or regular injections. 
 The number of patients recruited fell below the original target, but not by much. 
Recruitment was disappointing because of the tendency to select patients on straightforward 
medication regimes and the low number of elderly patients on complex medication regimes. 
It is possible that this tendency arose because practice staff avoided choosing patients on 
complex regimes or chose patients they knew well or poor record keeping could have been 
the reasons (RDS 3 Draft Report, 1999, p. 65). 
 Patients were given a six-part prescription with red stickers indicating that they were 
on the project. The patients had freedom of choice of pharmacy (within the health authority 
boundaries) and could either hold on to the prescription instalments or leave them with a 
pharmacy of their choice. Levied patients had only to pay for the initial instalment. 
 Pharmacists presented with a pilot prescription had to carry out monthly reviews of 
the patients’ medication needs when they came for their medication to be dispensed. The 
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reviews involved seeing whether patients were taking their medicines as prescribed; whether 
they were suffering from any side effects and whether they needed a change in supplies. 
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REPEAT DISPENSING SCHEME TYPE 4 (RDS 4) 
 
Repeat Dispensing Scheme 4 was the largest of the pilots covering four geographical areas. 
The pilot had four main objectives:- 
 
 to see whether a pharmacist managed repeat dispensing scheme could affect the cost of 
repeat prescribing and to estimate the size of this effect 
 to test whether the repeat dispensing scheme affected the quality of patient care 
 to test whether the payment of financial incentives to pharmacists in the repeat dispensing 
schemes affected the size of either of these effects 
 to test the effect of pharmacist versus patient retention of prescription instalments on the 
size of these effects 
 
In order to test these objectives, the schemes differed from each other in important respects. 
With respect to pharmacist remuneration, all of the pharmacists who took part were paid a fee 
of £1.83 for each monthly instalment of each item, but pharmacists in two of the areas were 
paid a percentage of any savings made as a result of non-dispensing of items on the repeat 
prescription. In two of the schemes the patients held the prescription instalments and in two 
the pharmacists held them. The prescriptions were specially designed. This case study is 









RDS 4.1 Patient choice No % savings 
RDS 4.2 Patient registration No % savings 
RDS 4.3 Patient choice % savings 





REPEAT DISPENSING SCHEME TYPE 4.1 (RDS 4.1) 
PILOT’S MAIN CHARACTERISTICS 
 
Pilot type: Repeat dispensing 
Patient groups targeted: Patients on repeat medication based on 
randomised selection and excluding patients who were on controlled drugs; 
HRT or contraceptive pill alone (but if on HRT and medication for 
hypertension were included) 
Expected number of patients recruited: 1,250 
Actual number of patients recruited: 991 
Referral source(s): GP practice (receptionists). CPs if patients already went 
directly to the pharmacist and had been randomised by the practice. Practice 
then asked the CP to recruit 
Number of participating pharmacies: 43 (ranging from having anything 
between 1 and 238 patients; 11 pharmacies had 50+ patients) 
Pharmacist remuneration: £1.00 per patient recruited plus a dispensing fee 
of £1.83 per item on the prescription whether the item was dispensed or not 
during the three-month intervention phase. No percentage of savings made 
Pharmacist reviews’ location: Pharmacy 
Number of participating GPs: 5 GP practices 
GP remuneration: £2.00 per patient recruited plus a printer 
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In this pilot, the repeat dispensing scheme was based on a system where the patient could 
choose which pharmacy to get their instalments dispensed from and they did not have to 
continue to use the pharmacy where the initial dispensing took place. The patients had to hold 
on to the prescription instalments.  It was also one of the pilots where the pharmacists did not 
get a percentage of savings made.  
The patient group included people who had been on medication for at least 12 
months; were over 16 years old; had agreed to take part in the study; were not on HRT, the 
contraceptive pill or surgical appliances alone and were not on controlled drugs. The 
prescriptions were specially designed, in triplicate, coloured pink and stamped to show that 
they were project prescriptions.  
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REPEAT DISPENSING SCHEME TYPE 5 (RDS 5) 
PILOT’S MAIN CHARACTERISTICS 
 
Pilot type: Repeat dispensing 
Patient groups targeted: Patients on repeat medication excluding those on 
HRT 
Expected number of patients recruited: 350 
Actual number of patients recruited: 350 
Referral source(s): Identified from PMRs and screened for suitability by 
CPs and GPs 
Number of participating pharmacies: Seven 
Pharmacist remuneration: £30.36 per patient per three-month cycle plus 
drug costs paid  
by PPA as normal (without the dispensing fee if items were undispensed) 
Pharmacist reviews location: Pharmacy 
Number of  particpating GPs: 2 GP practices 
GP remuneration: £15. 00 handling fee per patient 
Freedom of choice of pharmacy: Pharmacist-held prescription instalments  
(Prescriptions were valid for three months) 
 
RDS 5 was a repeat dispensing scheme that aimed to investigate the feasibility of a 
community pharmacy based repeat dispensing procedure for patients with regular repeat 
prescriptions. Its objectives included:- 
 
 To develop a suitable and appropriate methodology 
 To identify appropriate patient groups 
 To evaluate the benefits from the perception of the patients, the GPs and the pharmacists 
 To identify barriers and constraints to the implementation of a repeat dispensing practice 
 To make recommendations on new forms of remuneration 
 
Two GP practices took part based in two different localities. One of the practices was based 
in a suburb situated on a busy road and served by seven pharmacies. The second practice was 
in a multi-ethnic inner city area and served by three pharmacies. Seven pharmacies took part 
in the scheme, four of which served the first practice and three of which served the second. 
 Pharmacist remuneration was patient centred rather than item driven; the aim was to 
improve patient care through a service that monitored adherence and reviewed medication. 
GPs were reluctant to get closely involved in the project. Their role involved screening 
patients identified by the pharmacy PMRs and screened by the pharmacists for their 
suitability for the project. They were paid a £15.00 handling fee per patient.  
 In this pilot patients on repeat medication were targeted and it excluded those on HRT 
and asthma medication. The patients were selected by random after screening pharmacy 
PMRs. Those who agreed to take part had to use the same pharmacy throughout the three-
month intervention cycle. The patients identified the pharmacy they wanted to use when they 




EXTENDED ADHERENCE/PHARMACEUTICAL CARE SCHEMES 
 
 
EXTENDED ADHERENCE SCHEME TYPE 1 (EAS 1) 
PILOT’S MAIN CHARACTERISTICS 
 
Pilot type: Extended adherence support 
Patient groups targeted: Mainly elderly and confused 
Expected number of patients recruited: 200 
Actual number of patients recruited: 63 
Referral source (s): Hospital pharmacists; social/care workers; district 
liaison nurses; occupational therapists; community (psychiatric) nurses; 
sheltered housing wardens; private care agency staff; Age Concern; 
Crossroads; GPs 
Number of participating pharmacists: 16 
Pharmacist remuneration: £40.00 fee per assessment and £30.00 follow-up 
fee 
Pharmacist reviews’ location: Domiciliary 
Number of participating GPs: 2 GPs referred patients into study 
GP remuneration: £100 to cover administration NB: introduced part-way 
through the study 
 
EAS 1 Health Authority piloted an extended adherence service based in two different 
localities. The pilot had a number of objectives:- 
  
 To consider whether community pharmacists could identify  
patients who needed help with adherence  
 to identify target patient groups  
 to establish reasons for poor adherence 
 to develop an appropriate referral system to identified  
community pharmacists  
 to improve safe and effective use of medicines 
 to reduce drug wastage   
 to establish the resource implications of the service. 
 
Sixteen pharmacists took part, carrying out domiciliary visits to patients referred into the 
scheme by a variety of different sources. Seven of these worked in independent pharmacies 
(six were proprietors), three worked for a small group and seven worked for a multiple. The 
pharmacists visited the patients in their homes to assess their adherence to their medications 
and to take action to help them if any problems were identified or to recommend action to the 
patients’ GPs. The pharmacists received a fee of £40.00 per assessment and £30.00 per 
follow up visit. The patient selection criteria were broad and 63 patients participated. The 
majority was over sixty and nearly half of them were housebound. There were several 
referrals sources in this scheme, including care workers, district nurses, social workers, 
pharmacists and doctors. The GPs’ role was minimal. They were one of a number of referral 
sources who had to refer patients who met the inclusion criteria into the scheme.  They were 
paid a fee of £100.00 to cover administration costs.  
 This project had similar problems to those encountered by RDS 1. The number of 
patients actually recruited fell well below what was anticipated. There were a number of 
reasons for this. First, the multiplicity of referral sources might have led to a sense of diffused 
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responsibility. Second, there seems to have been some difficult local politics between the 
LMC and the LPC. This led some GPs to reject the scheme altogether because they felt they 
had not been sufficiently consulted about it. Financial incentive for the GPs to get involved 




EXTENDED ADHERENCE SCHEME TYPE 2 (EAS 2) 
PILOT’S MAIN CHARACTERISTICS 
 
Pilot type: Extended adherence  
Patient groups targeted: Hypertension 
Expected number of patients recruited: 300 
Actual number of patients recruited: 261 (146 intervention; 115 control) 
Referral source (s): Community pharmacists 
Number of participating pharmacists: 23 pharmacies (12 intervention; 11 
control) 
Pharmacist remuneration: Intervention pharmacists: £100 fee to cover 
training and  
patient recruitment and £100 per patient in four phases linked with return of 
study data. 
 Control pharmacists: £100 fee to cover training and patient recruitment 
Pharmacist reviews’ location: Pharmacy 
Number of participating GPs: N/A 
GP remuneration: None 
 
EAS 2 Health Authority ran an extended adherence project in liaison with a local university 
department. In the light of research showing that many patients suffering from hypertension 
do not adhere to their prescribed treatment and evidence of patients’ self-regulation of 
treatment, adjustment of doses and intermittent reductions or cessation of treatment, the 
project aimed to bring a patient-centred approach to adherence (EAS 2 Project Protocol, 
1997, p. 1). Its objectives included:-  
 
 the improvement of understanding of patients’ beliefs and information needs  
 the design and testing of a practical educational intervention tailored to patients’ own 
concerns and needs 
 the measurement of outcomes including self-reported adherence, patient satisfaction, 
repeat prescription frequency and blood pressure control   
 the dissemination of the findings to patients, patient organisations, health professionals 
and health service managers 
 
The study differed from the other adherence projects in that it targeted a single patient group 
and in that the interventions took place in the pharmacy or by telephone rather than in the 
patients’ homes. It was also unusual in that it was based on a randomised control study 
whereby the pharmacists were divided into intervention and control groups. The scheme was 
offered to all 94 pharmacies in the area and 23 pharmacies participated: 12 intervention and 
11 control. Patients were recruited through the PMR or by opportunistic selection on 
presentation of a prescription. The inclusion criteria were: all age ranges; both sexes; patients 
being treated only for hypertension; patients being treated for conditions in addition to 
hypertension; patients being treated for a short period of time (i.e. less than 2 years); patients 
being treated for a medium length of time (i.e. between 2 and 10 years); patients being treated 
for a long time (i.e. more than 10 years). The actual number of patients recruited fell a little 
short of the original target of 300, with 261 patients taking part. The intervention pharmacists 
recruited 146 patients and the control pharmacists recruited 115 patients. 
The intervention pharmacists carried out a pharmacy-based/telephone assessment of 
the patients recruited at month one, three and five. They answered patients’ concerns about 
their medicines, gave advice on adherence, advised the patients to go back to the doctors if 
necessary and/or made a recommendation to the GP where appropriate. The patients allocated 
to the control group received the usual care. All pharmacists got a lump sum of £100 to cover 
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training, patient recruitment and validation of hypertension with GP. Intervention pharmacists 
received £100 per patient in four phases linked with return of study data.  
The GPs in this scheme played a minimal role in this project. The LMC was informed 
of the project and got a copy of the protocol plus the GP briefing document. The study 
patients’ GPs received a project-briefing document and these GPs confirmed the diagnosis of 
hypertension and the time since diagnosis for each patient. They did not receive any 




EXTENDED ADHERENCE SCHEME TYPE 3 (EAS 3) 
PILOT’S MAIN CHARACTERISTICS 
 
Pilot type: Pharmaceutical care and adherence 
Patient groups targeted: Ischaemic Heart Disease 
Expected number of patients recruited: 300 
Actual number of patients recruited: 236 
Referral source (s): GPs; community pharmacists; cardiac nurses 
Number of participating pharmacists: 5 
Pharmacist remuneration: £25 per hour 
Pharmacist reviews’ location: GP surgeries 
Number of participating GPs: 8 practices, 17 GPs 
GP remuneration: None 
 
EAS 3 carried out a project aimed at improving the care of community-based patients with 
Ischaemic Heart Disease (IHD) through GP-Pharmacist collaboration. The project developed 
partly in response to the Health Authority’s need to introduce effective ways of reducing 
morbidity and mortality rates in the light of targets set out in Health of the Nation. It also 
developed out of a previous GP-pharmacist prescribing initiative in the area. All of the 
pharmacists who took part had been involved in this earlier scheme. The project had three 
main aims:-  
 
 to look at the use of six evidence-based interventions in patient management 
 to consider the effect of pharmacist-run review clinic on angina patients’  
quality of life  
 to examine  pharmacists’, doctors’ and patients’ attitudes towards the clinics.  
 
Five pharmacists took part in co-operation with seventeen GPs based in eight practices. The 
GPs, pharmacists and cardiac nurses selected the patients for review and the pharmacists ran 
the clinics focusing on the six interventions.  Three of the interventions related to life-style 
and included smoking cessation; physical activity and diet. The other three were therapeutic-
based, including, aspirin; beta-blockers and statins. Pharmacists also looked at the use of 
nitrates, although they did not originally intend to. The clinics took place in the general 
practices. 
 The patient inclusion criteria were patients aged between 45 and 75 years with stable 
angina and receiving four or fewer prescribed medications for IHD. A total of 327 patients 
who satisfied the inclusion criteria were invited to attend the clinics during the three-month 
recruitment period and 236 (72%) of these went (EAS 3 Report, 1998, p. 45). The 
pharmacists carried out face-to-face reviews with the patients at the start and the end of the 
five-month study period. Between these reviews they did two interim reviews by telephone. 
The pharmacists collected data on the six interventions. Patients completed the Seattle 
Angina Questionnaire (SAQ) at the first and the last review. The SAQ assessed the impact of 
the clinics on patients’ functional status and quality of life. The SAQ is a tried and tested 
measure of five aspects of IHD: physical limitation; anginal stability; anginal frequency; 
treatment satisfaction; disease perception. 
 The Health Authority commissioned independent evaluators based at a local 
university. The evaluators carried out a qualitative analysis of patient, GP and pharmacist 
perceptions of the clinics through in-depth semi-structured interviews. They  also carried out 
a statistical analysis of  the data collected on the six interventions and the SAQ (EAS 3 
Report 1998, pp. iii-viii). We have summarised some of the Health Authority’s findings in 






This study aimed to investigate the acceptability of various extended roles for community 
pharmacists to the key stakeholders, namely, the pharmacists, GPs and the patients; their 
impact on patient adherence and, in some of the main repeat dispensing projects, their impact 
on drugs costs. The study also aimed to consider the question of generalisability and 
feasibility. The following comments are based on research carried out in seven of the original 
pilots. These pilots reflect a mix of instalment and repeat dispensing schemes (RDS 1, RDS 2,  
RDS 3, RDS 4.1) and extended adherence and pharmaceutical care schemes (EAS 1, EAS 2, 
EAS 3). We are also commenting separately on drug costs savings for RDS 2, RDS 3 and 
RDS 5.  
 
5.1 GENERAL ACCEPTABILITY 
 
Simplifying a little, there appears to be a consensus of support in principle amongst the key 
stakeholders for community pharmacists extending their role into the management of 
medicines. The pharmacists welcomed their involvement in these pilots as a way of 
enhancing their professional development. For example, a pharmacist who took part in RDS 3 
said, 
 
‘I got involved from an interest in the possibility of 
pharmacy taking on a further role in medicines 
management. Yes, for professional reasons really’ 
(RDS 3 CP 3). 
 
Out of the repeat dispensing schemes, RDS 2 and RDS 3 were the most successful. In RDS 3, 
the Health Authority’s evaluation found that 84% of the pharmacists who took part in the 
study found it good or very good and only 4% found it poor (RDS 3 Final Report, 1999, p. 
97).  This satisfaction sprang partly from the pilots’ simplicity. In some ways, the services 
built on the pharmacists’ past experience rather than departed significantly from it. For 
example, a pharmacist who participated in RDS 3 said,  
 
‘it was different in as much as we interviewed the 
customers and had to keep the prescription 
instalments and fill in the forms. But it wasn’t a 
major change though’ (RDS 3 CP 2) 
 
Moreover, the repeat dispensing pilots did not entail a marked increase in workload and the 
pharmacists viewed them as a way of increasing their job satisfaction.  
 RDS 4.1 had more mixed reviews. Three of the five pharmacists we spoke to 
supported the scheme, but two of these commented that better schemes were going on 
elsewhere. Two of the pharmacists were very critical of the pilot. Those who objected to the 
scheme did so mainly because they thought that the patients’ freedom of choice of pharmacy 
inhibited continuity and was confusing in terms of patient payment in the case of levied 
patients. Given that  patients’ freedom of choice was maintained and pharmacists did not 
receive a percentage of any savings made, this pilot offered pharmacists little incentive. 
Out of the extended adherence schemes included here, the pharmacists were quite 
satisfied in EAS 1 and very satisfied in EAS 3. Their satisfaction stemmed from getting out of 
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the dispensary and being able to work on issues they thought were compatible with their 
training. When asked about their reasons for getting involved in the schemes, the pharmacists 
typically cited professional development. For example a pharmacist who took part in EAS 1 
said she got involved 
 
‘very much for professional development [and 
because I] saw it as an opportunity to move beyond 
simply handing over tablets and to get follow-
through’ (EAS 1 CP 1).  
 
Pharmacists who took part in EAS 3 were the most enthusiastic. This was because they had 
had previous experience of projects and the Health Authority, backed by local university-
based evaluators, had a well-defined purpose also rooted in strong previous experience. 
EAS 2 was less successful from the pharmacists’ point of view. This result could have 
stemmed from our having spoken to the wrong pharmacists. However, five of the twelve 
intervention pharmacists were interviewed and two others were contacted. Neither of these 
wanted to be interviewed and both expressed some dissatisfaction. It seems more likely that 
the reason for the pharmacists’ reservations about this pilot stemmed from the extra workload 
relating to a control study. All of the pharmacists we spoke to reported that the documentation 
they had to complete at each patient review was too lengthy and time-consuming. Noting that 
the project co-ordinators had been supportive throughout the trial, a member of the LPC 
remarked that ‘part of the problem is that practice research is very different from pure 
academic research’ (EAS 2 LPC rep), suggesting that the study’s academic component was 
why the pharmacists encountered problems. 
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The doctors who took part in these pilots accepted the pharmacists’ interventions in so 
far as they saw them fulfilling a support function, filling a gap in their own abilities to help 
with patient adherence and a group to whom they could delegate responsibility. Disregarding 
set-up difficulties stemming from lack of co-operation from GPs, there is evidence that the 
schemes relating to dispensing (RDS 2, and RDS 3) found greatest favour amongst GPs. This 
was because the doctors thought that pharmacists could take some of the burden out of repeat 
prescribing. There is general agreement that repeat prescribing in the UK not only takes up a 
lot of GP time, it does not necessarily ensure high quality care (Dowell et al., 1998, p. 1858). 
There is evidence from our research that the doctors appreciated the pharmacists’ 
interventions because it took away some of the burden associated with repeat prescribing. GPs 
who took part in RDS 3 for example (where patients were supplied with a prescription based 
on six monthly instalments) noted that the pilot resulted in patients either coming half as often 
or cutting down visits about minor complaints. One doctor said, 
 
‘we saw less of the patients. Probably about a third 
of the people who did it, we saw them half as much 
as before. We used to see them every three months 
for things like blood pressure reviews’ (RDS 3 GP 
1). 
 
And another said, 
 
‘it [workload] was reduced in the sense that I didn’t 
have to sign the scripts every day. They were all 
done in one go…it wastes a lot of time signing 
repeats every day’ (RDS 3 GP 1). 
 
Some of the dissatisfaction expressed by doctors in RDS 2 stemmed less from principle than 
from practical issues such as patient recruitment, difficulties synchronising supplies and 
difficulties arising from use of a special prescription.  
Out of the extended adherence projects, EAS 1 got most support from the GPs who 
took part (despite reports of lack of GP co-operation in the set-up stage). This was because the 
doctors perceived a need amongst the elderly population for help with adherence which they 
did not have the time to do.  One GP, for example, said, 
 
‘Oh yes, over the last thirty years I’ve had worries. 
I’ve seen old people in their homes and when I’ve 
checked what they’ve had, there has been an 
amazing amount of unused drugs’ (EAS 1 GP 1). 
 
And another said, 
 
‘I just thought it might be something to help people 
at risk of compliance problems. I had thought there 
was a small but significant problem’ (EAS 1 GP 2). 
 
In contrast, doctors involved in EAS 2 and EAS 3 showed greater reservations and more 
mixed views. Their ambivalence reflected more deep-rooted concerns amongst doctors 
towards pharmacists taking on more clinical roles. These differences suggested that GPs 
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welcome an extension in community pharmacists’ roles, but in limited areas. EAS 2 and EAS 
3 differed from EAS 1 in that they were more clinically orientated. 
Patients It was more difficult to gauge patients’ attitudes towards pharmacists 
extending their roles because we were confined to investigating the attitudes of patients who 
consented to take part in the pilots and could not access those who refused to participate. Our 
findings on patients’ views therefore stem from the limited number of focus groups with 
patients, our interviews with the pharmacists and doctors combined with the local sites’ 
findings.  
Out of the repeat dispensing schemes, patient support seemed strongest in RDS 2 and 
RDS 3 and weakest in RDS 1 and RDS 4.1. In the former, patients enjoyed the convenience of 
visiting a pharmacy rather than a surgery and having their medicines prepared by the 
pharmacists for pick-up. In a focus group discussion, one of the patients said that they liked 
the pilot because it was 
 
‘more convenient definitely. Making an 
appointment to see a doctor to get a prescription is 
so time wasting. Not just for the doctor, but for 
yourself too’ (RDS 2 PT 1). 
 
Patients who took part in RDS 3 held similar views. 
The study that showed the greatest level of patient dissatisfaction was RDS 1. This 
was because the scheme stood alone in so far as one of the patient groups it targeted was 
people suffering from drug addiction difficulties. It is likely that drug addicts being treated 
with methadone or benzodiazepines would feel some unease about having to receive 
observed consumption. As one pharmacist said, 
 
‘They’re drug addicts. They want to take a few 
valium and then sell the rest on the streets. They 
wanted the doctor to take “observed consumption” 
off the packet…They didn’t like that’ (RDS 1 CP 
2).  
 
The doctors also highlighted the difficulties stemming from the kinds of patients targeted in 
this project. They reported that a number of patients refused to participate. One of the GPs, 
for example, said  
 
‘one patient disappeared completely, she didn’t like 
it at all. The other one found it difficult and 
inconvenient because he used to have his 
prescriptions monthly. And the third one, she was a 
drug addict, in the end I had to take her out of the 
trial because she just wasn’t following the protocol’ 
(RDS 1 GP 1). 
 
In RDS 4.1, however, the professional stakeholders thought that the patients were ambivalent 
because they found the new system and prescriptions confusing. 
Out of the extended adherence schemes, patient support seemed highest for EAS 1 and 
EAS 3 and weakest for EAS 2. In EAS 1 and 3 there were reports that the patients found the 
time the pharmacists could spend with them helpful and that they benefited in terms of their 
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understanding of their medications and adherence (EAS 1) and in terms of support for making 
life-style changes (EAS 3). A patient who took part in EAS 1, for example, said, 
 
‘As it was it was just prescriptions, doctor, 
pharmacists and there was nobody you could 
actually…now it’s been marvellous…your chemist 
coming to visit you and converse with you about 
your medicines’ (EAS 1 PT 4).  
 
In contrast, EAS 2 pharmacists reported that some patients found the reviews time-consuming 
and repetitive. As one pharmacist said, 
 
‘They [the patients] didn’t like having to answer the 
same questions over and over again…it was using 
up a lot of their time’ (EAS 2 CP 4). 
 
This dissatisfaction might also have reflected the fact that a number of the patients had been 



































5.2 ADDED VALUE: ADHERENCE 
 
Given the potential health risks and cost to the NHS of poor patient adherence to medications, 
one of the principal goals in these pilots was to assess their impact on adherence. All of the 
projects were in some way concerned with this issue, however, the question of comparability 
arose because of the different ways the sites measured adherence. Some of them looked at 
adherence in terms of pick-up rates of prescriptions and others measured adherence from 
patients’ self-reports, using different questionnaires. Moreover, it is difficult to gauge the 
pilots’ impact on adherence because the local sites had difficulties measuring changes and 
because we had to rely on stakeholders’ subjective perceptions. In the following we shall 
briefly describe the findings for each site included in this report.  
 






No/Minimal Improvement  
or Mixed Views 
 
 





































*This table is based on the professional stakeholders’ perceptions of whether patient adherence had improved as 
a result of the pharmacists’ interventions. If the stakeholders did not think that the interventions had positively 
affected adherence, we asked them whether they thought they had the potential to improve adherence. Given the 
focus on subjective perceptions, the results have to be treated with caution. We found that the stakeholders 
perceptions sometimes differed from the local evaluations’ results (e.g. in EAS 2 & 3). 
 
EAS 1  It was not possible objectively to measure impact on adherence in this study because 
the tool used to measure changes (a medicines cognisance test) provided unreliable results 
because of low documentation return and some anomalies in the findings. However, all of the 
pharmacists who completed the Health Authority’s post-intervention questionnaire thought 
that adherence had either always improved (53%) or that it had sometimes improved (47%) 
(EAS 1 Final Report, 1998, pp. 26-7). Moreover, the pharmacists made a number of 
interventions that could have benefited the patients. The Health Authority reported that 
medicines care cards were provided in 20 cases; there were 19 cases of communication with 
GP; 17 interventions involved the provision of a monitored dosage system; changes were 
made to the timing of doses in 13 cases; patients were advised to consult their GP or nurse in 
5 cases; pharmacists organised medicines in 4 cases and other interventions included the 
supply of non-child resistant caps or different size bottles (EAS 1 Final Report, 1998, p. 21). 
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 Most of the pharmacists thought that they had been able to help patients through 
advice or the provision of monitored dosage systems. For example, one of them said, 
 
‘Some of them I made reminder charts for and 
linked their tablets to meal times because a lot of 
them forget when to take their medication. And 
there was a specific case, a blind lady. She was 
completely blind and we hadn’t realised it. So 
we’ve been able to highlight it on the PMR and now 
we put her tablets into different size bottles so she 
can tell which is which’ (EAS 1 CP 2). 
 
EAS 2 The local evaluators have not published their findings yet, however, the project co-
ordinator has reported that the service significantly affected patient adherence. There was 
some support for this view amongst the pharmacists we spoke to, despite the practical 
difficulties involved in providing the service. One pharmacist, for example, said it benefited 
 
‘some of [the patients], yes. They [the patients] 
might say, for example, about diuretics, “I didn’t 
know I had to keep taking them”. So that was sorted 
out’ (EAS 2 CP 1). 
 
And another pharmacist said the intervention had an impact 
 
‘on their understanding, yes, definitely. Particularly 
some elderly patients who didn’t know why they 
were taking it and who were confused about side 
effects. So I think the intervention helped to clarify 
things here…But I’m not sure whether it affected 
the way they took things’ (EAS 2 CP 2). 
 
However, others were a bit more sceptical. When asked whether the intervention affected 
adherence, one pharmacist said, 
 
‘In general, I’d have to say no. One patient did 
benefit…We made some alterations for her. She 
was having trouble swallowing powdery tablets, so 
we gave them to her in capsules. Also, with her 
codeine tablets we suggested that she took them at a 
different time of day. But just one patient out of 
eleven isn’t very significant really’ (EAS 2 CP 4). 
 
EAS 3 Our findings on this pilot’s impact on adherence are based on our own 
interviews and the results of the local evaluation carried out by a university department. The 
local evaluation reported changes in patient management relating to the pharmacists’ delivery 
of six evidence-based interventions and based on an assessment of 208 patients (i.e. those who 
completed the trial: 88%). Looking specifically at adherence, the local evaluation found that 
the pharmacist interventions had a minimal impact. Having collected baseline data at the start 
of the study, the local evaluation found that self reports showing ‘very good’ levels of 
adherence to aspirin, beta-blockers and statins did not change significantly as a result of the 
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reviews. At the outset, 91% of patients taking aspirin, 91% of patients taking beta-blockers 
and 86% of patients taking statins reported that they ‘never forgot a dose’. At the end of the 
reviews, these figures reached 92%, 93% and 89% respectively (EAS 3 Final Report 1998, p. 
69). However, it should be noted that these figures derived from patients’ self-reported 
estimates of how often they forgot a dose and, for this reason, may be unreliable. 
Moreover, there was general agreement amongst the pharmacists we interviewed that 
the interventions had improved patients’ adherence to their medications.  One pharmacist 
said, 
 
‘Certainly with some of them [adherence] 
improved. Basically you found that they were 
missing out tablets and taking them at the wrong 
time. For example, they’d miss out a night-time 
dose…because it was more convenient to take it in 
the morning’ (EAS 3 CP 2). 
 
Another pharmacist said that the interventions had been beneficial in so far as they helped to 
identify patients who had not had their cholesterol levels tested for a long time (EAS 3 CP 1).  
In terms of the lifestyle intervention, the study showed that by the final review the 
number of current smokers had decreased by 3%; that the number of patients who reported 
taking little or no exercise fell by 8% (there was no change in the proportion of patients 
overweight). In terms of  therapeutic interventions, by the final reviews there had been an 
increase of 8% of patients taking aspirins (and this figure excluded only those who could not 
take aspirin); there was little change by the end of the review for beta-blockers; the number of 
patients prescribed statins increased by 13% (EAS 3 Final Report, 1998, p. vi). 
RDS 1 It was difficult to measure the impact of this scheme on patients’ adherence 
because the trial was only for a short period and because only a small number of patients took 
part (RDS 1 Draft Report, 1998). There is evidence from our interviews with pharmacists that 
the impact was minimal. They thought that this was because the service differed little from 
past practices, especially in relation to drug addicts. The exception being when the patients 
received observed consumption and, in another case, where a patient was particularly 
confused and benefited from daily instalments. Most of the pharmacists we interviewed did 
not think that their intervention necessarily improved patients’ adherence, unless they took 
their medicines under observed consumption. However, the pharmacist working in the 
multiple said that her intervention had improved the patient’s adherence because,  
 
‘he gets confused and he had to come in each day so 
there was one less thing he had to worry about. 
Safety-wise it helped too because there are drug 
pushers on the street and he didn’t have any 
supplies’ (RDS 1 CP 3). 
 
Moreover, even if there had been no obvious improvement as a result of the pilot, the 
pharmacists thought instalment dispensing had the potential to improve adherence. 
The doctors similarly thought that the trial did not really affect patient adherence. 
However, most of them could see potential benefits in these areas.  They thought that there 
were some obvious candidates to target, including illicit drug users, patients suffering from 
TB or mental health conditions and the confused and elderly. One GP pointed out that it was 
invaluable for drug addicts’ health because  
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‘the fact they were having it on a daily basis, yes – 
because if they take them all at once they’re at risk 
of overdose and then, over the next few days, they 
don’t have any and so they get withdrawal 
symptoms and are at risk of fitting’ (RDS 1 GP 4). 
 
RDS 2 From our interviews with pharmacists and doctors who took part in this 
scheme, there are positive signs about its impact on patient adherence, the pharmacists 
thought their interventions benefited patients in different ways: by making them more aware 
of what they were taking, preventing build-up of unnecessary medicines in the home and 
reassuring them that they were taking their medicines properly and helping them to use them 
properly. One pharmacist recalled that one of his patients had a large amount of unused 
aspirins in his home. He took these away and made sure that the patient got the required 
monthly amount  (RDS 2 CP 4). Another pharmacist discovered that her patient, who 
suffered from diabetes, had not been monitoring her glucose levels properly (RDS 2 CP 6). 
Another said, 
 
‘Some of them improved the way they were taking 
them, or, by talking to them, I gave them the 
confidence to carry on the way they were doing it’ 
(RDS 2 CP 5).  
 
Out of the doctors we spoke to there was also some grounds for optimism. Some thought that 
the schemes did improve patient adherence. Those who thought they did not, believed that in 
the long-term schemes likes this could make a positive contribution to adherence, particularly 
amongst the elderly (who were able to visit the pharmacy) and people stabilised on long-
terms medication for chronic conditions such as asthma. One doctor said, 
 
‘For certain categories of medicines it worked well. 
I suppose we’re talking about diabetic medication. 
This worked well because once people are stabilised 
they stay on the same dose for the rest of their life’ 
(RDS 2 GP 1). 
 
RDS 3’s consideration of adherence was based on patient pick-up rates. It defined 
adherence as the situation when a patient picked up their instalments within a week (either 
way – early or late) of the anticipated pick-up date. Although patient pick-up rates varied 
between GP practices, across all of them, 63% of patients did not pick up their prescriptions 
on time and 10% of patients only picked up one or two prescriptions or none at all (RDS 3 
Final Report, 1999, p. 70). These data are interesting but cannot tell us about the trial’s impact 
on adherence because there are no comparable pre-study data.  
From our interviews, none of the pharmacists thought that the service had 
significantly affected adherence and some thought it had not at all. One pharmacist said, 
 
‘It probably improved adherence in using inhalers. 
And, it gave the opportunity to talk to them (the 
patients) about other things they were using even if 
they weren’t on the prescription’ (RDS 3 CP 2).   
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However, those who thought there had not really been much of an impact believed this was 
because many of the patients recruited on to the scheme were so well established on their 
medications that they had ironed out any problems. As one pharmacist said, 
 
‘I think quite a few of the patients had been on 
medication for years…and it was a very routine 
thing for them. They all knew what they were 
doing’ (RDS 3 CP 3). 
 
  RDS 4.1 The pharmacists had mixed views over whether their interventions had 
affected patient adherence. Three thought that the interventions had no impact on patient 
adherence. One of these thought  so on the grounds that he already helped patients in this area 
and spent time going through their medications with them until they were well established 
(RDS 4.1 CP 5). However, two thought that improvements had been made. One recalled the 
case of a patient who had not been taking calcium supplements with her steroid treatment. 
After explaining to the patient that not taking the supplements could cause osteoporosis, she 
started taking them regularly (RDS 4.1 CP 1). In another case the dispenser reported two of 
the patients suffering from arthritis had been stockpiling tablets. On discovering that they only 
took the tablets when they were in pain, the pharmacist told them that they had to take their 
medication regularly (RDS 4.1 DISP/CP 4). 
 The doctors were unsure about whether the scheme had affected patient adherence. 
One of them thought that the pharmacists had not had enough time to get involved in this 
issue (RDS 4.1 GP 2). However the other two thought that it might have affected adherence in 
some cases and that such a scheme could probably benefit elderly patients on polypharmacy 
(RDS 4.1 GP 1; RDS 4.1 GP 3). 
 
Adherence discussion 
There is not, therefore, a lot of evidence that these pilot schemes significantly affected patient 
adherence. One possible reason for this is that some of the patients who took part were not 
necessarily the most appropriate ones because they had been well established on chronic 
medication and were able to manage their medicines well. A number of pharmacists and 
doctors who took part in the pilots mentioned that the patients enrolled were not always the 
ones who had noticeable difficulties with their medicines. None of the pilots included in this 
report dealt with patients starting a drug therapy. RDS 6 (which is ongoing) did focus on this 
issue, however, and its organisers have reported that initial results are encouraging.
2
  
Moreover, it was unlikely that radical changes would take place because of the short-
term nature of the trials. It should be noted that although there was some doubt about whether 
the actual pilots had affected patient adherence, the pharmacists and doctors we spoke to 
were unanimous in believing that the pharmacists’ interventions had the potential to improve 
patient adherence, and consequently, health, in the long term. Furthermore, the anecdotal 
evidence provided by the pharmacists was promising. 
However, if the stakeholders’ perceptions were accurate, there is reason to suppose 
that EAS 1 and EAS 3 were the most successful in terms of adherence. This relative success 
could have been because in these two projects the pharmacists held the reviews outside the 
pharmacy, either in the patients homes (EAS 1) or in the GP surgeries (EAS 3). This suggests 





5.3 ADDED VALUE: COST DATA ANALYSIS 
 
In this section we outline the cost savings analyses carried out on data supplied by  three of 
the pilot sites:  RDS 2, RDS 3 and RDS 5.  Differences in study design makes a comparison 
of the savings made as a result of non dispensed items interesting and it is possible to 
speculate about some possible causes of the variation in savings across sites.  However, it is 
important to bear in mind the limitations of such comparisons when we are not comparing 
like with like.  The size, design and entry criteria for patients in the three sites differed and 
these differences will be discussed in the light of the results.  Data received from the three 
sites also differed in the items supplied and methodology used in estimating non-dispensed 
drug costs.  We have made adjustments where necessary to make comparison possible on as 
many issues as possible and, where necessary, we shall explain the adjustments with the 
required caveats. 
First, we shall outline the methodology used for the analyses and the measurement 
used as indicators of savings made for the purpose of assessing the relative success of pilot 
intervention schemes.  Second, we shall provide an overall summary of the results from each 
of the three sites allowing some broad comparisons.  Third, we shall explore any apparent 
variations in drug savings in relation to known factors in each study. Finally, we shall 




Collection of data 
Three pilot sites have provided data:  RDS 2, RDS 3 and RDS 5. Data relating to site RDS 3 
was collected and entered by the project manager, and supplied to us in spreadsheet form.  In 
RDS 2 the project manager supplied us with raw data which we entered and analysed using 
the format used in RDS 3. Being a larger study, RDS 5 collected and entered the data 
according to their own framework. The site provided us with their analyses and hard copies 
of results supplied in tables and we entered these into a spreadsheet for secondary analyses 
and extrapolated to enable comparison with the other two sites.  
 
Estimation of savings on non-dispensed drug items 
For RDS 2 and RDS 3, each individual drug item was included in a dataset with details of the 
prescribed cost and quantity.  The dispensed cost of each of these items was also entered, 
being the full prescribed cost, part of the prescribed cost if fewer than the full prescribed 
quantity were dispensed, or a zero dispensed cost if no part of the item was dispensed to the 
patient.  Details were also entered relating to the pharmacy, GP practice and BNF chapter of 
each item so that the total saving made on non-dispensed items in each of the resulting 
subgroups could be made.  Although this saving was a theoretical sum it was estimated as the 
difference between the full cost of prescribed items and the actual cost of dispensed items. 
In RDS 5, the patient sometimes received a prescription for PRN medication which 
could be dispensed in quantities at the discretion of the pharmacist rather than a stated 
quantity which could be either fully or partially dispensed.  Partly as a result of this aspect of 
the study, the RDS 5 research team felt calculation of the theoretical cost of non-dispensed 
items was not appropriate. Instead, it used the number of items dispensed as a proportion of 
the number of items prescribed and applied this ratio to the cost of these dispensed items to 
derive a proxy estimated cost of items non dispensed.  It was felt that this method would 
better reflect the costs of PRN medications and quantities of drugs that were only partly 
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dispensed. This difference has implications for the direct comparison of RDS 5 with results 
from the other two sites.  This alternative approach to estimating the level of saving on non-
dispensed items was subsequently applied to findings from RDS 2 and RDS 3, to allow a 
more appropriate comparison of overall performance of the intervention trial. 
 
Measuring the impact of community pharmacy interventions on drug cost savings 
The design of the studies and the nature of the data available makes it difficult to decide how 
best to evaluate the success of each of the intervention trials.  For example, the total cost of 
non-dispensed drugs can be calculated as described above.  However, this is of limited value 
without reference to the full prescribed cost of the drugs.  Similarly, the enormous variation 
in the cost of individual items makes any focus on costs misleading because it does not 
necessarily reflect the level of input by the pharmacist.  For example by focusing on financial 
savings, a pharmacist who chooses not to dispense one expensive item would appear to have 
made a greater contribution to the trial than another pharmacist who advises a large number 
of patients that they already have sufficient less costly drugs, such as analgesia for the 
forthcoming month. Another measure that would address this problem is the number of 
prescribed items that have not been dispensed.  This count is also of limited value when 
considered in isolation.  For example the number of items withheld is only meaningful 
relative to the number of items prescribed.   
In order to address these dilemmas, the present analyses have measured savings in 
four different ways.  The results of these should be considered in combination before making 
any conclusive judgement of the success of each intervention trial.  These four measures are:- 
 
 As a total saving  
 As a percentage of prescribed costs  
 Number of non-dispensed items 
 Average saving across these non-dispensed items 
 
These performance indicators have been estimated for each site over the entire six-month 
period and per instalment.  In addition, they have been calculated separately for each 
subgroup of, pharmacy type, drug category, pharmacy and GP practice. As an additional 
individual measure across the whole period, the average costs per prescription item was 
calculated based on the numbers of items prescribed and the total costs of items dispensed. 
All analyses were carried out for the two sections of the trial period; instalments 1-3 and 
instalments 4-6.  These have not been reported in this section as there were no variations 
observed that were different from those reported or of any additional interest. 
 
Cost analysis results: overall summary 
The highest level of saving was made in the RDS 5 study where the estimated cost of non-
dispensed items was £21,443, which is 33% of the prescribed cost (see table 5.3.1).  
However, caution should be exercised in interpreting these results given the differences in 
study design and analysis.  There was also some increase in savings over the six instalments 
rising from 26% of the dispensed cost in the first month to 48% in the sixth month of the 
study.  Throughout the period, there was a total of 2,384 non-dispensed items, the average 
saving being £8.99.  It is not possible to examine savings on individual items or to calculate 
the median saving or the range of individual savings.  The average cost per item prescribed 
based on the cost of items dispensed, was found to be £5.51.  
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Table 5.3 1 TOTAL EXPENDITURE ON DISPENSED ITEMS AND ESTIMATED COST OF NON-
DISPENSED ITEMS IN PILOT SITE RDS 5 
 
Instalment Expenditure on 
dispensed items (£) 
Saving on non-
dispensed items (£) 

































































TOTAL 43,238 21,443 33 64,680 
 
 
The project at RDS 2 also made considerable savings of £4,793, representing 13% of the 
prescribed cost (See table 5.3.2).  There was an increase in savings within the first three 
months and, after a decrease between the third and fourth months, a further increase over 
months four to six.  There was a total of 696 non-dispensed items during the study, with an 
average saving of £6.89.  The median saving was £2.94.  Savings on the individual items 
ranged from just one pence for paracetamol up to £153 for immunosuppressants. The average 
cost per item prescribed based on the cost of items dispensed was £7.13.  
 
Table 5.3.2 TOTAL EXPENDITURE ON DISPENSED ITEMS AND COST OF NON-DISPENSED 
ITEMS IN PILOT SITE RDS 2 
 
Instalment Expenditure on 
dispensed items (£) 
Saving on non-
dispensed items (£) 

































































TOTAL 32113 4793 13 36906 
 
The savings made by project RDS 3 were not as marked, although this was a smaller study, 
(see table 5.3.3).  There was a saving of £439, or 3% of the prescribed cost.  There were 65 
non-dispensed items, having an average saving of £6.75, and the median saving was £3.75.  
Savings ranged from seven pence for aspirins up to £54.00 for some corticosteroids.  There 
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was no increase in savings over the six months of the study.  The average cost per item 
prescribed based on the cost of items dispensed, was found to be £6.39.  
 
Table 5.3.3 TOTAL EXPENDITURE ON DISPENSED ITEMS AND COST OF NON-DISPENSED 
ITEMS IN PILOT SITE RDS 3 
 
Instalment Expenditure on 
dispensed items (£) 
Saving on non-
dispensed items (£) 

































































TOTAL 15,448 439 3 15,886 
 
 
When the method for estimating the cost of non-dispensed items used in RDS 5 was applied 
to the other two sites, the percentage saving in relation to the prescribed cost in RDS 3 
remained at 3%, and the saving at RDS 2, increased marginally from 13% to 15%.  This 
suggests that this particular difference in methodology was not responsible for the larger 
saving in RDS 5. We shall consider possible explanations for this differential later. 
 
Results: Variations in savings on non-dispensed items 
We have looked at savings on non-dispensed items in four different ways, namely, pharmacy 
type; BNF categories; GP practice and pharmacy. We shall deal with each of these separately 
in the following. 
 
Pharmacy type 
In two of these three sites, the greatest savings were made by independent pharmacies, 
constituting a saving of 17% of prescribed costs and 49% of prescribed costs in RDS 2 and 
RDS 5 respectively.  In RDS 3, a much higher number (41) of items were withheld at the 
multiple pharmacies and these corresponded to a higher percentage (7%), of prescribed cost, 
than the savings made by the other types of pharmacy.  These results are shown in tables 
5.3.4 & 5.3.5. 
 There could have been a number of reasons for the independents’ greater contribution 
than the multiples’ in the two cases. First, the independent proprietors were paid directly for 
the interventions whereas in some cases the multiple employees did not get the remuneration 
themselves. Second, the independent proprietors might have been more motivated than the 
employee pharmacists because of a perceived threat to their livelihood and third, there might 
have been more continuity with the patients in the independents because the multiples often 
have a number of pharmacy staff working at different times. It is more difficult, however, to 
explain the greater savings made by the multiples than the independents in RDS 3. 
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Table 5.3.4 TOTAL SAVINGS ON NON-DISPENSED ITEMS AND SAVINGS AS A PERCENTAGE OF 
PRESCRIBED COSTS BY TYPE OF PHARMACY IN PILOT SITES RDS 3, RDS 2 AND RDS 5 
 
Pharmacy size RDS 3 RDS 2 RDS 5 



















































TOTAL 439 3 4,793 13 21,443 33 
 
Table 5.3.5 NUMBERS OF NON-DISPENSED ITEMS AND AVERAGE SAVING PER NON-
DISPENSED ITEM BY TYPE OF PHARMACY IN PILOT SITES RDS 3, RDS 2 AND RDS 5 
 
Pharmacy size RDS 3 RDS 2 RDS 5 




















































TOTAL 65 6.75 696 6.89 2384 8.99 
 
 
BNF Drug category 
The drug categories of non-dispensed items have been compared for two sites (see tables 
5.3.6 & 5.3.7). When the saving in terms of prescribed cost was examined, in RDS 3, the 
main savings were made on medication for skin, nutrition and blood, and endocrine disorders.  
If the number of items non-dispensed is used, however, the largest number of items non-
dispensed were for the cardiovascular system.  The greatest average saving was in the 
respiratory drugs group, having an average saving of £19.00, with a 6% saving in relation to 
prescribed costs being in the corticosteroids inhalers.   
 When the drug groups are divided into subcategories, there are some interesting 
findings.  A marked saving of 13% was made in the group of drugs for psychoses although 
with such small numbers in the study, it is not advisable to draw conclusions from these 
results.  There was a 19% saving on diabetic drugs, although it is not possible to distinguish 
between oral hypoglycaemics and equipment for monitoring blood sugar.  Another large 
saving of 41% was made on the subgroup of drugs used to treat anaemia, with 19% being 
saved on vitamin preparations.  Non-dispensed corticosteroid eyedrops presented a saving of 
75% and emollients withheld represented a 35% saving.  While it is helpful to examine 
exactly where the savings were made in relation to drug subgroup, caution must be exercised 




Table 5.3.6 TOTAL SAVINGS ON NON-DISPENSED ITEMS AND SAVINGS AS A PERCENTAGE OF 
PRESCRIBED COSTS BY BNF CATEGORY IN PILOT SITES RDS 3 AND RDS 2 
 
BNF RDS 3 RDS 2 





Central Nervous System 
Infections 
Endocrine System 
Obstetrics, Gynaecology, and Urinary-tract Disorders 
Malignant Disease and Immunosuppression 
Nutrition and Blood 
Muscoloskeletal and Joint Diseases 
Eye 
Ear, Nose and Oropharynx 
Skin 
Borderline Substances 










































































Table 5.3.7 NUMBERS OF NON-DISPENSED ITEMS AND AVERAGE SAVING PER NON-
DISPENSED ITEM BY BNF DRUG CATEGORY IN PILOT SITES RDS 3 AND RDS 2 
 
BNF RDS 3 RDS 2 





Central Nervous System 
Infections 
Endocrine System 
Obstetrics, Gynaecology, and Urinary-tract Disorders 
Malignant Disease and Immunosuppression 
Nutrition and Blood 
Muscoloskeletal and Joint Diseases 
Eye 
Ear, Nose and Oropharynx 
Skin 
Borderline Substances 


































































In RDS 2, there was a more even spread of savings across the drug categories.  If the 
48% saving on wound management products and elastic hosiery are disregarded, the highest 
saving relative to the prescribed cost was in relation to drugs to treat infections, with a 31% 
saving.  The saving was wholly made on antibacterial drugs within this BNF chapter heading.  
Similarly to RDS 3, there was 24% of prescribed cost saved on drugs for the nutrition and 
blood.  These savings were evenly spread across the subcategories of vitamins, minerals and 
anti-anaemia remedies.  There was also a 21% saving on skin medication, this being largely 
on wound cleansing preparations and topical circulatory products.   
Also in line with the results from RDS 3, the highest number of non-dispensed items 
was in relation to cardiovascular drugs with 194 being felt to be not needed.  These were 
diuretics (48 items), and antiplatelet and anticoagulents and protamine (57 items).  116 items 
for the respiratory system were not dispensed.  Of these, 64 were for bronchodilators in 
inhaler form and 8 for oral bronchodilators.  Of the remaining items, 41 were corticosteroid 
inhalers.  This respiratory category also had the second highest average saving at £12.00.  
(The highest average saving was for immunosuppressants for a single patient who did not 
require a prescription because he obtained his drugs from the hospital outpatients). 
It is interesting to examine this breakdown of subcategories further.  A high 
proportion of topical rubiefacients for soft tissue problems such as rheumatics was non-
dispensed (46%) although this finding is not noticeable at the main chapter level.  There was 
a 30% saving on drugs acting on the nose, in an aerosol form.  Chapter 6 of the BNF covers a 
wide range of endocrine system drugs and equipment.  When this group is broken down, the 
savings were largely for diabetic drugs, with 52 non-dispensed items having a saving 
corresponding to 26% of the prescribed cost.  Within this group 6.1, the saving on insulin was 
42% of the prescribed cost and on diabetic equipment such as syringes and urine or blood test 
strips, 31%.  A saving of only 8% was made on oral hypoglycaemics.   
 
General Practitioner Practice 
Seven practices took part in the study in RDS 3.  The savings made ranged from less than 1% 
of prescribed costs to 9% in practice D and 29% in practice H, although this was misleading 
since it was the result of one saving in the first instalment.  When the number of items 
withheld was considered, the lowest number was one item in practice H, ranging up to 23 
items in Practice D, the exact reverse of the results based on the saving expressed as a 
percentage of the prescribed cost.  This demonstrates the danger in focusing on one measure 
in isolation.  There was no apparent increase in savings by any practice over the six 
instalments. 
Four practices participated in RDS 2.  Savings ranged from 10% to 17% of the 
prescribed costs.  Performance in the four practices was similar with three practices having 
over around 200 items withheld compared to only 67 non-dispensed items in the fourth 
practice, although these did represent 10% of the prescribed cost.  The trend across the six 
months in each practice mirrored the increases in the sample as a whole as a result of patient 
reassessment, as discussed above. 
RDS 5 focused on only two practices, which achieved similar results of 33% and 34% 
of, prescribed costs in each case.  The volume of prescriptions varied markedly, however, 
with 1,925 items being non-dispensed to patients of practice 1 and only 459 items not given 
to patients of practice 2.   
 
Pharmacy 
In relation to pharmacies used, there was also some variation.  In RDS 3, there were 54 
pharmacies out of a possible 57 who participated.  The small number of non-dispensed items 
in this study makes any interpretation of these results difficult.  It is useful to consider only 
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those pharmacies that received prescriptions from study patients in at least 3 of the 
instalments.  This reduces the number to 36 and has the advantage of excluding one 
pharmacy with a 89% saving incurred on one month, which could serve to distort the results.  
Only 13 of these pharmacies made savings equivalent to at least 1% of the prescribed cost.  
The average saving across these was 3%, reflecting that of the study overall and the median 
saving was <1% because so few pharmacies made any significant saving.  It was possible to 
examine the performance of individual pharmacists in relation to whether or not they had 
received training as part of other health authority work.  This showed that those who had 
been involved in previous work made greater savings and there was also an increase in the 
level of savings per instalment over the 6 month period by those who had received health 
authority training for previous research work (see table 5.3.8). 
The twelve pharmacies in RDS 2 made savings ranging from 1% to 22% of the 
prescribed costs, with numbers of non-dispensed items ranging from 4 to 229.  The average 
and median saving per pharmacy were 10% in both cases.  The same pattern of relative 
increases over the six months as discussed above was seen as in the study as a whole. In this 
pilot all pharmacists received the same training on commencement of the trial and none had 
been involved in health authority work previously so there were no differences in training. 
RDS 5 involved seven pharmacies in the study.  Savings relative to prescribed costs at 
this site ranged from 17% to 59%, although these results should be interpreted with extreme 
caution as in the case of this latter pharmacy, savings of 80% and 86% appear to have been 
made in the last two months of the study.   
 
Costs analysis discussion 
By far the largest financial saving corresponding to non-dispensed prescription items was 
made by RDS 5.  This was the largest of the three samples and made a saving of £21,443, or 
33% of the prescribed cost, compared with a saving of 13% in RDS 2 and 3% in RDS 3.  It is 
useful to consider some differences in the three studies, which could account for some of this 
enormous differential.   
 
Patient recruitment criteria 
In RDS 5, patients were recruited to the study subject to their consent if they had received 
repeat prescriptions for two consecutive months.  In RDS 3, potential recruits were identified 
as those who had been given at least six repeat prescriptions, and in RDS 2, subjects were 
deemed suitable if taking prescribed repeat medication for chronic conditions for at least six 
months.  This difference in entry criteria may have influenced the high rate of saving in RDS 
5 if some patients required medication for longer than two months but not for the duration of 
the six-month intervention period.  Of the 8% attrition rate during the trial, the RDS 5 
research team attributed some of this to misapplication of patients to the original repeat 
dispensing status. 
 
Sample attrition  
Although the RDS 5 project team did not consider poor adherence to be a large problem 
overall, some patients withdrew from the scheme and returned to ordering drugs with 
conventional white prescriptions.  The problem was thought to relate mainly to pharmacy six 
towards the end of the period when the pharmacist and also the surgery dispensing the 
prescriptions become less motivated to encourage patients to remain on the scheme and a 
large number of patients withdrew.  A problem arose, however, because from the pink 
prescriptions in circulation it appeared that the drugs from these patients were not being 
required without regard to the fact that alternative white forms were also being used.  Some 
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cases were identified by the team and treated as part of the 48 patients lost to the study over 
the sixth month period, but it is possible that this occurred unnoticed in other cases. 
 
Prescriptions not presented or not collected  
By virtue of the study design and methodology used for estimating the cost of drug items not 
dispensed in RDS 5, it is possible that the savings figure included cases which would have 
been classified in other studies as prescriptions not presented or not collected, rather than 
solely those items not dispensed at the patient’s specific request.   
The low level of savings made in RDS 3 may be partly attributable to the high 
proportion of prescriptions not collected by patients.  This issue is discussed in detail in the 
Health Authority’s final report. Overall, 63% of patients did not collect the prescription on 
time.  This may have been because the patient already had sufficient medication at home for 
the forthcoming month.  The research team at RDS 3 calculated the theoretical saving that 
would have been made had all prescriptions been collected.  This was based on the average 
prescription cost for each practice.  When the items not collected were assumed to be not 
dispensed, savings ranged from 11% to 47% of the total estimated prescribed costs, with a 
mean saving of 24% and a median saving of 20%.  This is arguably a more accurate 
comparison with the results of RDS 5.   
Under scheme RDS 2, it was known that 13 patients who had been given trial 
prescriptions did not present them at instalment one.  These were excluded from the study.  A 
small number of prescription instalments were not collected on time, and of these 43, all were 
either collected late or delivered to the patient by the pharmacist. 
 
Patient monitoring by pharmacist 
Although each of the three studies was undertaken over a six month intervention period, RDS 
2 and RDS 5 involved two repeat dispensing periods of three months whereas in RDS 3, 
patients were issued with six separate white prescriptions at the start of the trial, one for 
presentation each month during the trial.  In this scheme, the pharmacist was responsible for 
interviewing patients with a questionnaire and would recommend a return consultation with 
the doctor at any point if the patient’s condition required medical reassessment.   
Under the scheme in RDS 5, patients could go to the surgery to request the second 
repeat prescription or if they preferred, the pharmacist would request it from the practice on 
their behalf.  Although patients were not required to consult the doctor at one time during the 
period, the pharmacist monitored the patient at each visit and referred to the GP where 
necessary.   
Patients participating in RDS 2 were similarly not required to revisit the GP during 
the period but the pharmacist had to complete a thorough full medicine review with each 
patient at the end of the first three month period before the second prescription was requested.  
This review removed any medicines considered unnecessary and is reflected in the results in 
table 2, where an increase in saving is made over the months 1-3 and then a reduction in 
instalment 4, after the prescription has been reviewed. 
 
Remuneration methods 
It is interesting to consider the possible impact of the different remuneration methods 
employed by each of the three sites.  These methods are outlined in detail in Table 5.4.1.  In 
RDS 3 the dispensing fee was paid on all items including those not dispensed.  This system 
has the advantage that it does not create any disincentive to non-dispensing by the 
pharmacists.  When compared to the system in RDS 2 where the dispensing fee was paid as 
normal only on each prescription item dispensed, thus providing such a disincentive, we 
might expect the savings to be greater in RDS 3, if the fee structures were having an effect on 
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dispensing behaviour.  The results do not support such an hypothesis and the significantly 
greater savings made in RDS 2 suggest that the per item system of payment to pharmacies did 
not influence dispensing decisions. 
In contrast to the item based payment systems in RDS 2 and RDS 3, the remuneration 
method employed in the RDS 5 study was that of an enhanced capitation-style fee paid per 
patient to cover project participation and dispensing.  We might speculate that the large 
savings made in this study relative to the other two sites might be related to this method of 
remuneration, although there is no evidence to support a causal effect.  The method does not 
create any incentives or disincentives to dispensing but the larger sums of money paid in a 
single payment may have been more salient to pharmacists than the monthly smaller fees paid 
in the other sites.  Together with the identification card issued to patients in the study and the 
specially designed prescription forms used, the capitation fee might have served as a 
reminder of the special status of patients in the study, reinforcing pharmacist and patient 
identity as participants.  If the remuneration method did have an impact on savings, this 
capitation method of fees would appear to be the most successful. 
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Table 5.3.8 TOTAL SAVINGS ON NON-DISPENSED ITEMS AND AS A PERCENTAGE OF PRESCRIBED COST BY INSTALMENT IN RDS 3 ACCORDING 
TO WHETHER OR NOT THE PHARMACIST HAD BEEN INVOLVED IN PREVIOUS HEALTH AUTHORITY RESEARCH 
 
 Instalment 1 Instalment 2 Instalment 3 Instalment 4 Instalment 5 Instalment 6 TOTAL 
 £ % £ % £ % £ % £ % £ % £ % 
 
Pharmacist had 



























































































TOTAL 68.65 3 99.96 4 53.94 2 68.44 2 60.69 2 87.20 4 438.88 3 
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Patient registration with a pharmacist 
Patient registration with a designated pharmacist may have contributed to the larger 
savings in RDS 5 and RDS 2 compared with RDS 3.  Patients in RDS 3 did not 
register with a pharmacist but could present the repeat prescription each month at any 
pharmacist in the area.  In some cases the pharmacist held on to the prescription at the 
patient’s request for the three month period, but in other cases, the patient took the 
prescription away until the next instalment was due.  This suggests that if patients 
were attending a variety of different pharmacies during the trial period, there may be 
less opportunity for the pharmacist to develop a rapport with them and to become 
familiar with their medication and medical conditions.  However, in practice, over 
90% of patients used the same pharmacy throughout the trial period.   
In RDS 2 and RDS 5, the patient registered with a pharmacist who was 
responsible for monitoring them throughout the trial. In these schemes, but unlike 
RDS 3, pharmacists were paid a per capita fee for each patient registered, regardless 
of numbers of prescription items dispensed.  In addition, in RDS 2, the pharmacist 
also prepared the medication for collection on an agreed date.  If the medication was 
not collected, the pharmacist contacted the patient to remind them.  This would 
account for the lower level of prescriptions not collected compared with that in RDS 
3.  
 
Categories of drug savings 
Conclusions about types of drugs saved are not possible given the small numbers of 
items in some of the BNF chapter categories.  Explanations for the patterns observed 
can only be speculative without knowledge of the reasons patients had for choosing 
not to request individual prescribed items.  However, some consideration of the broad 
variations is interesting.  It is unfortunate that details of drug category are not known 
for prescribed items in RDS 5. Overall, it appears that the items such as inhalers, 
creams, insulin, syringes and eye-drops which were not dispensed in finite unit doses, 
are those which patients tended to refuse.  This may be because they did not use the 
prescribed quantity each month.   
Another explanation for items not being required is that patients did not take 
the drugs as prescribed if they felt they were not essential.  This may have been the 
case in relation to the high proportion of vitamins and anti-anaemia preparations, such 
as iron or folic acid.  Non-adherence may also have accounted for the numbers of 
diuretic items not dispensed.  Alternatively, patients may have purchased vitamins and 
iron tablets over the counter and then declined the prescription.   
There were a large number of anti-coagulant drugs non-dispensed and in 
relation to aspirin 75 mg, this may have been because the patient regarded them as 
non-essential or chose to buy them.  In terms of other anti-coagulants, doctors tend to 
supply prescriptions for warfarin in a variety of doses for patients who are on variable 
doses determined by frequent blood monitoring.  In these cases, patients may have 
accumulated a surplus of small dose tablets that they chose to use during the trial.   
 
Costs analysis summary  
The results of the three pilot intervention schemes have shown that there is the 
potential to make some quite considerable financial savings on prescription items 
which are not required by patients and as a direct result of community pharmacist 
intervention.  The exact level of these savings varied considerably across the three 
sites possibly as a result in differences in study design and research methodology 
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employed.  Although this section has made comparisons among the three sets of 
results wherever possible, any overall cost evaluation based on direct comparison is 
very difficult given the very different frameworks, data characteristics and results of 
the three studies.   
The results of short trials such as these six-month interventions do not take 
account of stores the patient may have at home, which they use over the early part of 
the period.  It could be argued that a longer intervention would be required to ensure 
that the effects of patients storing and using up stocks of medicines would be evened 
out. 
As highlighted elsewhere, the financial aspect of such pilot schemes is only 
part of project outcome and should not be considered in isolation from the other 
factors.  However, an analysis of these savings on drug costs is important to an 
evaluation of the projects and ideally should be linked to outcome measures such as 
patient health status and any change in this over time to inform some cost benefit 
analyses.  
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5.4 GENERALISABILITY AND FEASIBILITY 
 
By generalisability and feasibility we mean the schemes’ potential for being ‘rolled 
out’ nationally and aspects of the pilots that seem important to successful 
implementation. There was general support for ‘rolling out’ the pilots nationally 
amongst the pharmacists we spoke to. The exception was EAS 2 where pharmacists 
thought that the pharmacy based reviews were not feasible because they were too time 
consuming. As one of the pharmacists put it 
 
‘You couldn’t roll that scheme out because it 
wasn’t designed to be rolled out. It was just 
to see whether some check on adherence 
could be sorted out. But there was too much 
involved in it to become a routine thing’ 
(EAS 2 CP 1). 
 
 There is also a need to take account of the appropriateness of particular 
schemes in particular demographic areas. Schemes targeting people suffering from 
drug addiction or TB are mainly relevant in inner city areas where problems such as 
these are prevalent. For example, one of the pharmacists who took part in RDS 1 said 
the scheme 
 
‘could work where the situation warrants it. I 
can think of lots of places where it might be 
a waste of time, such as in rural areas…it 
wouldn’t necessarily work there’ (RDS 1 CP 
1). 
 
Some of the professional stakeholders also thought that the repeat dispensing schemes 
targeting chronically ill patients stabilised on long-term therapy were most appropriate 
in areas with a high level of stability amongst the populations. For example a GP who 
took part in RDS 2 said 
 
‘Our practice profile is probably particularly 
suitable to the scheme because we’ve got a 
stable population. But in an inner city, it 
would be difficult’ (RDS 2 GP 3).  
 
Despite this general support for rolling out the projects in principle, the stakeholders 
thought that modifications would be needed for the services to work routinely. There 
were a number of factors that seemed critical to successful implementation and a 
number of factors that seemed to act as barriers to implementation. Our comments on 
the following have been informed by interviews with the local project managers and 
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Factors Important to  Successful Implementation 
 
We have identified five factors that would be key to successful implementation. These 




In terms of future implementation, there would be a need for some sort of central co-
ordination that was locally based. Three of the project managers felt that their projects 
worked largely as a result of their own efforts in so far as they kept all the various 
workers focused on the common task.  The project manager at RDS 2 put the pilot’s 
success down to the Health Authority’s decision to employ a manager to ‘chivvy up’ 
data collection. In RDS 3 the project manager kept in close contact with all the 
relevant stakeholders throughout the set-up period and she explained the scheme’s 
success in terms of good communication and public relations and adopting a facilitator 
approach through meetings. Some of the most successful projects involved liaison 
work during the projects’ set-up stage. For example, the local pharmaceutical adviser 
in RDS 2 had forged links with GP practice. 
Two of the project managers mentioned the importance of the health 
authorities (EAS 2 and EAS 3). One of them thought that successful implementation 
might depend upon a steering group consisting of the HA; the LPC, the LMC and a 
medical adviser. In the light of these studies, it seems that this mixture would be vital. 
For example, specific problems arose where the LMC was not consulted. In EAS 1 the 
local difficulties with the LMC meant that a number of doctors refused to recruit 
patients on to the scheme.  A member of the LMC said  
 
‘the whole project emerged through debate 
between the pharmacists and the Health 
Authority. There was no medical input at all 
in deciding the area to be looked at. The 
protocols and the terms of reference, all 
these things were just presented to us. So the 
LMC said that we should have been 
consulted in the first place’ (EAS 1 LMC 
rep). 
 
Choice of pharmacists 
Targeting the right kind of pharmacist also seemed important to the projects’ relative 
success. EAS 3’s local co-ordinator thought that this had been crucial to the pilot’s 
achievements. In this project, the pharmacists had all been previously involved in 
initiatives with GPs and they were very committed to extending pharmacy’s role into 
more clinical areas. This touches on the issue of motivation and one of the pharmacists 
who took part in this pilot thought that it would not suit all pharmacists. 
 
‘Not all pharmacists would be able to do it. 
Obviously you need a certain training. Some 
wouldn’t be prepared to do it. They just 
wouldn’t be interested…they wouldn’t want 
to leave the shop’ (EAS 3 CP 4). 
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However, it should be noted that this scheme stood out from the others in its greater 
clinical orientation.  
The success of the pharmacists’ services also depended upon suitable training. 
Most of the pharmacists we spoke to had previously done relevant CPPE distance 
learning packages and, at the start of the pilots, received training sessions provided by 
the various local health authorities. They all felt adequately skilled to take on their new 
roles, despite some initial lack of confidence. However, they thought that their 
participation in the training sessions had been important to their ability successfully to 
carry out the services. Two project managers (RDS 2; RDS 3) thought that 
pharmacists who had some kind of particularly relevant training prior to their 
involvement in the pilots performed better and were more able to deal with problems 
relating to the prescriptions (Informal conversation with CPPE rep). It should be noted 
that these findings are impressionistic. However, it has been possible to illustrate 
graphically the variations in savings made by pharmacists who had done previous 
project work and pharmacists who had not in RDS 3 (see figure 2).  
RDS 2’s project manager reported that locums working in ‘chain’ pharmacies 
did not perform well and she speculated that this could have been because they did not 
feel they had ownership of the project. Our own interviews confirm this. Pharmacists 
who felt that the project had been imposed on them and that they had no control over it 
were the least satisfied. One of the pharmacists in EAS 2, for example, said 
 
‘Well I didn’t [sign up for it]. I got lumbered 
with it! My predecessor signed up and 
wanted to get involved then…left the job 
and put my name down’ (EAS 2 CP 4).  
 
Pharmacists who took part in RDS 4.1 had similar misgivings that seemed to be linked 
to a lack of choice. As one put it 
 
‘[it] was because our surgery was involved. 
It was the doctors who agreed to participate 
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Remuneration for pharmacists is the source of some debate. The current system offers 
pharmacists little incentive for taking on medicines management  because their income 
depends upon the items they dispense. Given this dilemma, there has been some 
consideration of ways to link remuneration with an advisory service on the 
management of medicines (Harper et al., 1998, p. 947). The RPS recently appointed a 
working group to examine new ways of remunerating community pharmacists. 
Recognising that the current remuneration system, based on items dispensed, deters 
pharmacists from taking part in some activities, the working group put forward twelve 
possible models for remuneration based on five basic principles, which, in short, were 
predicated on providing the NHS with value for money in combination with an 




The schemes discussed here varied in the ways they remunerated the 
pharmacists and doctors (see table 5.4.1) and there seems to be some link between 
level of remuneration and success. In EAS 2 and EAS 3 the doctors were not 
remunerated because their role was minimal. In RDS 3 the doctors were paid £25.00 
per patient recruited. Partway through the study RDS 1’s research team also decided to 
pay doctors £25.00 per patient in two instalments. In RDS 2 the doctors were given 
£1000 to cover administration costs and a printer. In RDS 4.1 there was a fee of £2.00 
for each patient recruited. All the pharmacists were paid a variable fee for service 
depending on the interventions they made and the number of patients they registered 
on the projects. EAS 3 also paid pharmacists for attending training sessions. 
 It is possible that RDS 2’s success in patient recruitment compared with RDS 
1’s low recruitment reflected the differences in remuneration for the doctors who were 
the referrers. In RDS 2 doctors received £1,000 to cover administration and a printer 
and a number of them mentioned the payment as an incentive. Although RDS 1 paid 
doctors in the same way as RDS 3 in the end, the payment was not offered at the 
outset as in RDS 3. It was only introduced partway through the study in response to 
low recruitment. Moreover, RDS 4.1’s project manager thought that GP practices 
would have been more enthusiastic if they had been given more money and reported 
that a number of practices refused to get involved partly for financial reasons and 
partly for workload reasons.  
Some of the most dissatisfied pharmacists, moreover, had not been 
remunerated. In EAS 2, for example, some employee pharmacists commented on how 
they had not been remunerated themselves. When asked about remuneration one of the 
pharmacists said 
 
‘Our company pocketed most of it anyway! 
They gave us a proportion of it, which was 
OK. I thought what the independents got 
was reasonable’ (EAS 2 CP 3). 
 
And another said 
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‘It would have been nice if I’d got it. I 
remember thinking it was very generous’ 
(EAS 2 CP 4).  
 
In this context, it should be noted that out of the five pharmacists we spoke to who 
took part in this pilot, the only one to report being satisfied was an independent 
proprietor. 
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A recent study looking at community pharmacists’ attitudes towards extending 
their role found that however much pharmacists wanted to move towards the direction 
of pharmaceutical care, they did not see it as worth their while unless they were 
remunerated for the time spent providing services other than dispensing (Bell et al., 
1998, pp. 289-90). 
Our own research complements this study’s findings. The contradiction 
between seeking to make wider savings in the drugs bill and optimising community 
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pharmacists’ income through number of items dispensed came through a number of 
interviews. One pharmacist, for example, said 
 
‘At the moment I don’t get paid when I don’t 
dispense...If someone wants to pay me [to 
make savings] then I’d welcome that’ (RDS 
4 CP1). 
 
On the whole, the pharmacists we spoke to were happy to carry out these services 
because the health authorities remunerated them. A member of the LPC in EAS 1 said, 
for example, 
 
‘Proper remuneration would have to be 
given to the pharmacists. In this case, they 
were reasonably happy. It was just a trial. 
But the money wouldn’t be enough if it 
continued in the same way. It would have to 
be streamlined and then the remuneration 
they got for the project would be OK’ (EAS 
1 LPC rep). 
 
There was widespread support for a professional fee to compensate for loss of income 
from dispensing less.  
A unifying concern was that the services’ success depended upon having the 
appropriate support including an accessible supply of locum cover. The need for this 
was greatest in the pilots where the interventions took place outside the pharmacy. 
Pharmacists who took part in EAS 3 and carried out half-hour reviews with a number 
of patients strongly stressed difficulties finding locum cover. One of the pharmacists 
who took part in EAS 3 said, 
 
‘The problem was getting the locums. It’s 
not easy to find one. It’s a manpower 
problem really and it’s going to get worse’ 
(EAS 3 CP 2).  
 
However, the pharmacists who did the reviews in their premises also envisaged 
staffing implications if they had to work with more patients.  
 
Patient registration 
There has been growing debate about the possibility of introducing patient registration 
with pharmacies. Part of this debate has been linked with the issue of remuneration. 
Patient registration could provide the basis for paying pharmacists a capitation fee. In 
our interviews we explored the stakeholders views on registration. We did this in an 
open ended way, allowing the pharmacists to define registration in their own way and 
then probing them on the matter of whether patients should be compelled to register 
with a pharmacy. 
The repeat dispensing schemes differed from each other in terms of whether 
patients had to use the same pharmacy to get their subsequent supplies of medication 
after the initial instalment or whether they were free to use a different pharmacy at 
each instalment. In RDS 1, RDS 2 and RDS 5 the patients were asked to use the same 
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pharmacy throughout the trial.  In RDS 3 the patients could choose whether to hold 
onto the prescriptions or give them to the pharmacist. In RDS 4.1 the patients were 
asked to hold on to the prescriptions (see table 5.4.2).  
 




























If the aim is continuity of care, the repeat dispensing schemes depended on 
patients using the same pharmacy. Four of the six managers we spoke to thought that 
patient registration would be a prerequisite for ‘rolling out’ the repeat dispensing 
schemes. There is some evidence that pharmacists favoured the schemes where the 
patients had to go to the same pharmacy (RDS 2) or chose to in the vast majority of 
cases (RDS 3). Pharmacists who took part in RDS 4.1, where the patients were 
supposed to hold on to the prescription, complained that the patient choice led to a 
lack of consistency in care and problems tracking payments.   
In principle, pharmacists and GPs tend to favour patients regularly using the 
same pharmacy. Both groups believe that such a practice would enhance patient care 
because it would enable pharmacists to identify drug interactions, side effects and to 
build up a relationship with the patient. For example, a pharmacist who took part in 
EAS 2 said 
 
‘Yes, generally I think it’s [registration] a 
good idea. The reason is because you’re 
more likely to get medication sorted, more 
likely to spot something that happened 
between prescriptions, more likely to know 
about the patient and, when they buy OTC 
drugs, you’d be able to intervene if you saw 
a problem’ (EAS 2 CP 1). 
 
However, there was minimal support amongst pharmacists and even less 
amongst doctors for patients being compelled to register with a pharmacy. Although 
these stakeholders thought that patients’ regular use of the same pharmacy benefited 
patient care, they prioritised the principle of freedom of choice. They supported patient 
registration with a pharmacy so long as it was a voluntary arrangement and the patient 
could go elsewhere if practical considerations made it necessary or if they simply 
chose to. For example, one pharmacist said, 
 
‘Registration? It’s a good idea and a bad 
idea. There’s so much to sort out. What if I 
get on well with a doctor and he might 
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prompt the patient to go to me?…If the 
patient chooses, that would be a better way. 
So then you could give them a form to fill in 
and send it off to their doctors. So at least 
you wouldn’t be calling them in off the 
street’ (RDS 3 CP 4).  
 
An important issue when thinking about implementing patient registration is 
patient views. The RPS recently commissioned a survey looking at use of community 
pharmacies based on interviews with over 500 people. It found that there was a very 
high level of loyalty for repeat prescriptions in particular, with eight out of ten people 
using the same pharmacy (RPSGB, 1996, p. 16). Other studies have shown that 
younger customers are less likely regularly to use a single pharmacy than older ones.  
Another study found that 60% of users, both ordinary and high, were loyal to one 
pharmacy and that two thirds of both groups visited pharmacies about minor ailments. 
However, 25% would still go to their GPs. The study also found that ‘high’ users or 
people suffering from chronic illnesses tended to want more in terms of services from 
their pharmacists than ‘ordinary’ users (See Mays, 1994, pp.19-21).  
There is evidence that patients who took part in these pilot repeat dispensing 
schemes were happy to use the same pharmacy for all their prescription instalments. In 
RDS 4.1, where patients were supposed to hold on to the prescriptions, there were a 
number of reports of patients asking the pharmacists to keep them instead. In RDS 3, 
moreover, where patients could choose to use the same pharmacy or to use different 
ones throughout the trial period, 93% of the patients who took part used the same 
pharmacy for all their instalment prescriptions (RDS 3, Final Report, 1999, p 3). 
Patients who took part in the focus group discussion in RDS 3 also indicated that they 
would not mind regularly using the same pharmacy and would not oppose registering 
with a single pharmacy, although one of them commented that it would only be 
acceptable as long as the pharmacy had the appropriate supplies. However, it should 
be noted that the patients who attended the focus group represented a particular patient 
group – the majority was in their retirement and they suffered from chronic conditions.  
The matter of registration with a pharmacy touches on the wider question of 
choice in health care and the extent to which patients want it. There is evidence that 
despite government policies that have apparently given patients more choice, for 
example in relation to GPs, most patients tend to favour continuity. This  suggests that 
continuity of care is more important than choice for patients, especially those suffering 
from chronic illnesses (See Calnan et al., 1998, p. 333). Applying this to pharmacy, it 
might be that registration should be targeted at specific groups (elderly and/or patients 
with chronic conditions) and that once community pharmacy begins to be perceived as 
relating to patient care as well as dispensing, patient registration will be generally 
accepted. 
 
Targeting appropriate patients 
Successful ‘roll out’ would also depend on targeting appropriate patients. A recurring 
theme in our interviews with the key stakeholders was that patients who were 
knowledgeable about their medicines and adhered well to them were included and 
were not necessarily the most appropriate ones. The pilots discussed here recruited 
patients in a number of ways. In RDS 1 and RDS 2 the GPs referred patients on to the 
scheme. In RDS 3, practice managers, practice receptionists and GPs referred patients. 
In RDS 4.1 GPs were the main referral source but they could pass this responsibility 
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on to the pharmacists. In EAS 1 there were a number of referral sources, including 
hospital pharmacists, social/care workers, district liaison nurses, occupational 
therapists, community/psychiatric nurses, sheltered housing wardens, private care 
agency staff, Age Concern, Crossroads and GPs. In EAS 2 the community pharmacists 
referred patients from the PMRs and in EAS 3 GPs, community pharmacists and 
cardiac nurses were the referral sources (see table 5.4.3). 
 
















































































In terms of numbers, patient recruitment was disappointing in two of the pilots (RDS 1 
and EAS 1). There were specific difficulties in relations with the LMC in EAS 1. 
However, the problem of numbers could also have arisen because there were multiple 
referral sources leading to a sense of diffused responsibility. This scheme differed 
from the other extended adherence schemes in this respect. 
The recruitment difficulties in RDS 1 stemmed from the nature of the patient 
groups targeted. The problems with recruiting patients in an inner city area and 
patients suffering from drug addiction or mental health problems could be treated 
separately. The Health Authority’s community pharmacy facilitator thought that the 
disappointing recruitment arose partly because the scheme involved asking patients 
who were used to going to their pharmacy on a monthly basis to go every day or every 
other day. He noted that ethical problems were pertinent here, especially in relation to 
particularly vulnerable patients such as those suffering from depression. It would have 
been unfair to ask such patients to visit a pharmacy so frequently and then to 
withdraw this opportunity from them after the trial period.
4
 Recruitment of patients 
suffering from drug addiction was also difficult. It might be important to consider 
whether GPs who run specialist clinics are the most appropriate referral sources here. 
The project manager found that GPs who held special clinics for patients suffering 
from drug addiction or mental health problems recruited more patients than the other 
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doctors. The question of specific training for the pharmacists involved is also 
important given that recent research has shown that illicit drug users wanted privacy 
and appreciated pharmacists who did not appear to hold negative attitudes towards 
them (Matheson, 1998, pp. 104-12).  
In terms of type of patients recruited, there was disappointment in RDS 1, RDS 
3 and EAS 2. In RDS 1 there was disappointment because no TB patients were 
recruited on the scheme. As mentioned in the case study description, this gap arose 
partly because a centre specialising in helping patients with TB did not co-operate 
with the project.  In the other two schemes, it was felt that the patients who took part 
were not necessarily the most appropriate ones. In RDS 3 the project organiser was 
disappointed at the low number of patients on complex medication regimes. She 
thought this might have been because the practice staff chose patients they knew or 
patients who were on straightforward medication regimes (RDS 3 Final Report 1999, 
p. 95). In EAS 2 in contrast, the difficulty seems to have stemmed from recruiting 
patients from the PMRs. This was mainly because the information about patients’ 
drugs in the PMR records did not provide a full picture of the patients’ background. 
Two of the pharmacists thought this was key. One said that  
 
‘the patient recruitment process was a bit of 
a problem…If you send out a questionnaire 
to a random sample of patients and ask them 
to take part, well, you’re not necessarily 
going to get the right patients’ (EAS 2 CP 
2).  
 
And another one thought patient recruitment might have to be GP-led (EAS 2 CP 1). It 
seems likely that a specialist with in-depth knowledge of the patients’ histories would 
be needed for satisfactory targeting of patients.  
 
Possible Barriers to Successful Implementation 
We have identified five possible barriers to successful implementation: GP co-
operation; special prescriptions; paperwork; review setting and source of funding. 
 
GP views 
Relations between community pharmacists and GPs could present a barrier to 
implementing changes in community pharmacists’ roles. Past research has shown that 
GPs have mixed views towards pharmacist involvement in patient care. Based on a 
survey of 744 GPs, one study showed that while GPs welcomed pharmacist 
participation in some activities, such as reporting on adverse drug reactions, they did 
not favour their participation in more patient care oriented activities such as screening 
(Spencer and Edwards, 1992, pp. 1670-2). However, other studies have had more 
optimistic findings. A survey of doctors and pharmacists in the Bexley area found 
considerable agreement between doctors’ and pharmacists’ views on various aspects 
of extended role as proposed in the 1987 White Paper, Promoting Better Health 
(Woodward, 1992, pp. 99-100). A more recent evaluation of the role of clinical 
pharmacists in general practice found that GPs accepted the vast majority of 
recommendations made by pharmacists in repeat medication clinics (Burtonwood et 
al., 1998, pp. 678-80).  
 Our own research confirmed this ambivalence. There was evidence of 
widespread support for community pharmacists helping patients to manage their 
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medicines better or participating in repeat dispensing. The doctors supported 
pharmacists extending their roles into these areas because they thought pharmacists 
had the appropriate training for such activities and that greater use of these skills could 
help reduce the doctors’ workload and meet a need in the population for help with 
medicines taking. 
However, GPs had more reservations about pharmacists taking on more 
clinically orientated activities. Although it was not uniformly so, there was much more 
scepticism expressed about pharmacists carrying out activities such as screening for 
cholesterol levels, blood pressure and so on. These views surfaced mainly in the two 
schemes reviewed here that developed this aspect of the extended role, namely EAS 2, 
which focused on hypertensive patients and EAS 3, which focused on patients 
suffering from IHD.  
In EAS 3 the pharmacists were disappointed about their impact on the patients’ 
use of beta-blockers and one of them thought this was because the doctors did not 
want to do this: 
 
‘We were quite keen on getting people on to 
beta-blockers. We had Health Authority 
guidelines and we had to adhere to them. But 
they [the doctors] had their own ideas and, at 
the end of the day, it was up to them what 
they gave their patients’ (EAS 3 CP 3). 
 
The doctors’ reservations stemmed from their view that pharmacists did not 
have the relevant clinical training. The other reason for their reticence seemed to be a 
concern about pharmacists crossing the boundary between the professional roles and 
consequently undermining the doctor/patient relationship. As one LMC member said, 
 
‘My personal view is that I would be 
grateful for any advice from a pharmacist if I 
was prescribing something that was less than 
ideal. But it’s quite concerning for the GP if, 
for example, the pharmacist felt the 
medication was less than ideal and told the 
patient that. It would be quite undermining 
of the GP’s relationship with the patient. The 
patient might start to feel less confident in 
the doctor. So it should go the GP not the 
patient’ (EAS 2 LMC rep). 
 
 The pharmacists also had mixed views on relations between the two 
professions. Many of them commented on how good their relationships were with 
GPs. However, a number of them also mentioned that GPs were not always co-
operative. They thought that GPs felt threatened by some of their activities and were 
being obstructive. An LPC representative who took part in the EAS 2 pilot thought 
that one of the reasons it did not go as expected was a lack of GP co-operation.  
 
‘They [GPs] don’t like you recommending 
any intervention because they see it as a 
threat…it’s been like that in other projects 
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too. GPs generally haven’t been very co-
operative’ (EAS 2 LPC rep). 
 
This LPC representative thought that the pilot would have worked better if the GPs 
had been involved in the training and more closely involved in patient recruitment. An 
LPC representative in another project held similar views. 
 
‘Very few of the medics wanted to be 
involved. They said they wouldn’t have the 
time and didn’t want the paperwork – as 
usual. Unless there’s money going directly 
into their pockets, they don’t want to co-
operate’ (EAS 1 LPC rep). 
 
To some extent, the projects’ success depended on GP co-operation. A number of the 
project managers we spoke to mentioned some difficulties over relations with GP 
surgeries. There were reports of GP practices refusing to take part (RDS 4.1; EAS 1; 
EAS 3) and communication difficulties over practical issues (EAS 3). In RDS 1 the 
project manager reported that some of the GPs complained about data. In EAS 2 the 
project manager thought that some GPs had been concerned about blood pressure 
measurements and interference from ‘outsiders’. In a number of the other pilots too, 
pharmacists noted that GPs had not been present at the training sessions and that 
successful implementation in the future would depend upon doctors being aware of 
what the pharmacists were doing (RDS 1; RDS 2) 
These findings indicate a need for some kind of locally based forum that would 
facilitate co-operation between pharmacists and doctors. Some research has shown that 
GPs who work closely with pharmacists in a health care centre tend to develop a more 
co-operative approach than those working in isolation from pharmacists (Harding and 
Taylor, 1990, p. 464). In the Netherlands, the government and the Dutch equivalent of 
the RPS (KNMP) promoted the establishment of consultation groups consisting of 
GPs and pharmacists who met at two-monthly intervals to discuss treatment and 
prescribing (Mason, 1998, p.  635). It might be that the emergent PCGs could act, at 
least partially, in this way. 
 
Specially designed prescriptions RDS 1, RDS 2 and RDS 4.1 used specially designed 
prescriptions.  In RDS 1 the prescriptions were designed with reference to existing 
Methadone prescriptions FP 10 (MDA) and FP 10 (HP) (Ad) and developed as a 
special prescription (FP 10 IDP KCW). They allowed a maximum of 4 drugs in 14 
instalments over 28 days. They were coloured bright pink by the government printing 
office using carbonised paper with a duplicate; each prescription was numbered; 
pharmacists and patients had to sign for each instalment dispensing; a signature from 
the GP was needed to authorise observed consumption and patients whose 
consumption was observed also had to sign (RDS 1 Draft Report, 1998, p. 13). In RDS 
2 the prescriptions had a format similar to existing FP 10 and they were the same size. 
However, they came in three-part NCR paper form; each sheet was a different colour 
and each triplicate had a unique number and a separate printer was needed. RDS 4.1 
used computer generated tripartite prescription forms in NCR paper. They were 
designed in liaison with IT specialists in order to minimise disruption to practice 
software. The final version did not need to be reformatted but there was a need for a 
printer that was compatible with NCR paper.  
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The stakeholders had mixed views over the use of non-standard prescriptions 
and they caused more problems for doctors than for pharmacists.  In RDS 1 and RDS 
2 doctors reported that using non-standard prescriptions had hardware implications for 
the practices. For example, doctors or other practice staff dealing with the 
prescriptions had to switch between printers for different kind of print runs. Some of 
the doctors did not find this a problem. Others thought that the need for multiple 
signing was tedious (RDS 2 GP 3; RDS 2 GP 4) and one doctor commented 
 
‘The special pink prescriptions in triplicate 
were a trifle clumsy and the restriction on 
the number of items caused some 
inconvenience’ (RDS 2 GP 5).  
 
Some of the doctors felt that if the service became routine, this issue would have to be 
addressed and they would need a straightforward way of handling special 
prescriptions.  
In RDS 4.1 a lot of effort was put into designing prescriptions that would cause 
the least convenience possible for the surgeries. In response to concerns about GP 
workload and the problems involved in hand-written prescriptions, the project 
organisers worked with an IT company to arrive at a design that would be compatible 
with existing GP software. Surgeries that did not have printers that were compatible 
with NCR paper were provided with one. On the whole, the doctors did not seem 
unduly put out by the special prescriptions. However, one mentioned difficulties 
handling the triplicate prescriptions in the printer (RDS 4.1 GP 3). One of the 
pharmacists in this project also noted difficulties with the prescriptions, saying that 
they were too flimsy (RDS 4.1 CP 2). 
 The difficulties involved in using non-standard prescriptions were also 
illustrated in another repeat dispensing project (RDS 5), which has not been included 
as a case study in this report. The local evaluators found that the prescription caused 
some confusion both amongst practice staff and pharmacists. Initially, doctors 
sometimes forgot to sign all three sections of the triplicate and pharmacists made 
queries about what to do about controlled drugs; PRN quantities; multiple dispensing 
on the same form; endorsing the right-hand column; patient signatures (RDS 5 Draft 
Methods Document). 
 In contrast, RDS 3 used the usual FP10 prescriptions in six monthly 
instalments with a red permanent sticker on the bottom left-hand side to indicate that it 
was a study prescription. On the whole, the doctors we spoke to found this system of 
prescribing straightforward, grumbling only slightly about having to sign six 
prescriptions at the same time (RDS 3 GP 2). 
 
Paperwork 
Most of the project managers thought that paperwork would obstruct a ‘roll out’ 
nationally. However, there was general agreement that the problems of excessive 
documentation and data collection were research factors that would not necessarily 
apply after the procedures had been evaluated and implemented as general good 
practice. The pharmacists and GPs we spoke to shared this view. None of them (with 
the exception of EAS 3) thought that the paperwork associated with the pilots would 
be feasible in a routine service. They nearly all qualified their complaints with the 
view that the paperwork was linked to the projects being pilots. 
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Amongst the professional stakeholders, there was unanimous opposition to 
lengthy paperwork. Neither the doctors nor the pharmacists thought that the services 
could be implemented successfully without a reduction in paperwork. For example, 
although the pharmacists who took part in RDS 2 supported the pilot, they did not 
think it would work routinely with the amount of paperwork they had to do. As one 
pharmacist said 
 
‘It was total chaos having to ask all those 
questions…well not so much having to ask 
them as record them’ (RDS 2 CP 6). 
 
A GP (who valued the scheme she took part in) said 
 
‘The paperwork…was voluminous and not 
compatible with the GP’s life! We see a 
patient every five minutes…filling in all 
these forms, it was ludicrously over-
administered. But it was so valuable that I 
was prepared to do it for the pilot’ (RDS 1 
GP 2). 
 
These views were typical, with nearly every participant we spoke to holding them. 
However, the problems seemed particularly acute in EAS 2. In this scheme the local 
academic unit carried out a randomised control trial designed to measure objectively 
the affects of pharmacists’ interventions on patient adherence. The documentation 
associated with randomised control studies would not be relevant in a situation where 
a service became routine.  
However, where the pharmacists carried out clinical assessments of patients in 
a surgery setting (EAS 3), they thought that the documentation would be necessary if 
the service were to be implemented.  
 
Review setting 
Because they were concerned with dispensing, the RDS type schemes took place in the 
pharmacy (although in RDS 2 the pharmacists did make some domiciliary visits). The 
reviews centred on assessing patients for side effects, adherence and whether there was 
a need to make changes in the patients’ medication.  
The difficulties surrounding the pharmacy as a setting for the reviews was 
particularly acute where the pharmacists were dealing with people with drug addiction 
problems (RDS 1). Some of the pharmacists mentioned that having to observe a 
patient take their medicine was time-consuming and that it could be off-putting to 
other customers. Other research has shown that lack of privacy in the pharmacy is off-
putting to patients who might want to get advice on sensitive issues and that a 
designated consultation area could overcome this and enhance the pharmacists’ 
professional image by making customers take their advisory role more seriously 
(Harper et al., 1998, p. 947). So one way of getting around this issue would be to have 
a private counselling area. However, most of the pharmacists we spoke to saw this as 
ideal but unlikely because of resource implications. 
 The extended adherence/pharmaceutical care projects took place in a variety of 
settings: EAS 1 (patients’ homes); EAS 2 (pharmacy) and EAS 3 (doctors’ surgeries). 
Pharmacists who took part in domiciliary visits thought that they benefited patients 
  66 
because it gave them time to go through their medicines and that such visits also had 
the potential to prevent hoarding and to facilitate the safe use of medicines. EAS 3 
worked particularly well because the reviews took place in the doctors’ surgeries, 
allowing the patients privacy and longer than usual consultations. It has been reported 
elsewhere that the pharmacists and the patients thought that the practice was more 
suitable for the reviews than the pharmacy.
5
  
The pharmacy-based extended adherence project (EAS 2) was the least 
successful in terms of review setting. The pharmacists found it difficult carrying out 
lengthy reviews with the patients about how they were taking their medicines and side 
effects in the pharmacy. This could have been a product of the documentation related 
to a control study. It was generally agreed that reviews such as those carried out in this 
study were not feasible in busy pharmacies and that the patients found them tedious 
too.  
Wherever the reviews were held, the professional stakeholders perceived 
implications for staffing. These were particularly evident when the pharmacists had to 
leave the premises (EAS 1; EAS 3). While they enjoyed being able to work in a 
different environment where they could spend uninterrupted time with the patients, a 
recurring theme centred on the need for easy access to locum cover. 
 
Source of funding 
Two of the project managers raised the issue of pharmacist remuneration. They 
thought that pharmacists’ pay would require attention and that there might not be 
sufficient resources to provide incentives to apply the schemes across the country. A 
number of the pharmacists we spoke to reinforced this view. They thought that it 
would not be feasible to carry out the services routinely without the kind of 
remuneration they received for the pilots. However, they were sceptical about the 
prospects of getting adequate remuneration in the future. One LPC representative said, 
 
‘In the long term we could reduce the drugs 
bill and what we’d want is a share of that 
reduction. The treasury would quite happily 
put it back into their coffers and GPs would 
want a share of it. So we’d need to have 
some part of that saving’ (EAS 2 LPC rep). 
 
There is some evidence from the repeat dispensing schemes of greater savings being 
made in those pilots where the pharmacists received a fee. With respect to the 
extended adherence services, Primary Care Groups (PCGs) could be a possible source 
of funding. They are going to make use of pharmacists for prescribing advice and so 
there is potential for buying in services to help with adherence. However, the PCGs 
could not be a source of funding for repeat dispensing schemes because of the ethical 
issues involved in GPs directing patients to particular pharmacies. It might therefore 
be that repeat dispensing schemes could be rolled out as a national service.  
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6. CONCLUSION 
 
This study aimed to investigate the acceptability of these pilot projects; their impact on 
patient adherence and drug costs and their generalisability and feasibility. In this 
section we shall provide brief descriptions of the study’s conclusions. 
 
General acceptability 
With respect to general acceptability there is clear evidence of support for pharmacists 
extending their role into medicines management and repeat dispensing amongst 
pharmacists, doctors and patients.  The pharmacists were unanimous in their support 
for extending their roles on the grounds that it would enhance their professional status 
and contribute to an improvement in patient care. However, they also identified some 
aspects of the pilots that would need to be streamlined for them to work routinely, 
including paperwork, ways of selecting patients, resource issues such as remuneration, 
locum cover and review setting and co-operation from GPs. The patients welcomed 
the pharmacists’ activities as convenient and time saving, both in terms of their own 
time and GPs’ time. They also enjoyed the potential for building up relationships with 
pharmacists whom they perceived as well qualified to give advice on their medications 
and side effects. However, a number of the professional stakeholders reported patients 
withdrawing from some of the schemes and finding the changes in the system, 
especially for the repeat dispensing services, confusing. The doctors supported the 
pharmacists’ interventions because they thought they met a definite need amongst 
patients, especially the elderly, which they did not have the time to tackle. Their 
reservations focused not on pharmacists extending their roles as such but on 
pharmacists carrying out activities perceived to fall in medicine’s domain. 
 
Adherence 
With respect to the pilots’ impact on patient adherence and costs, there are also 
grounds for optimism. Although these pilots did not seem to have a dramatic impact 
on patient adherence, there was a consensus of opinion amongst the stakeholders that 
this was because they were too short term and that some of the patients included were 
not always the ones who needed the most help. There was general agreement that 
pharmacists could, in the long term, make a contribution to patient adherence. 
Moreover, the qualitative analysis highlighted anecdotal evidence of concrete benefits 
to a number of patients. Even though this occurred in a small number of cases it seems 
likely that, with more focused targeting of patients, the benefits in terms of adherence 
would be more marked.  
 
Drug costs savings 
There is also clear evidence that the pharmacists’ interventions in the three repeat 
dispensing projects discussed here impacted on drug costs, ranging from 3 % savings 
on prescribed drug costs in RDS 3 to 33 % in RDS 5. RDS 2 fell in the middle of these 
with a savings of  13 %. The variation in results could have stemmed from a number 
of factors, including those associated with study design and process. However, there is 
some indication of a case for patient registration given that those sites where it was a 
part of the service made the highest savings and there seems to be a case for 
pharmacists receiving a professional fee to compensate for possible loss of income 
from dispensing for the same reason.  
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Implementation 
Despite these findings, the schemes could only be implemented in the future if certain 
conditions were in place. It seems likely that there would be a need for some kind of 
central co-ordination; for targeting pharmacists who were strongly motivated for 
carrying out these extended activities and ensuring that the appropriate training was in 
place; appropriate financial incentives would also be critical as well as targeting 
appropriate patients and introducing some form of patient registration, although there 
is little support for obliging patients to register with a pharmacy. 
 The study also showed that there are a number of possible obstructions to 
rolling out these extended services. Problems arose over the level of paperwork; 
however, it was generally thought that this level was related to the services being 
pilots rather than inherent to the services. In the repeat dispensing schemes, difficulties 
arose over the specially designed prescriptions, especially for doctors. The setting of 
the pharmacists’ reviews also were problematic in some cases and suggests the need 
for consultation areas. Problems also arose over doctors views. While doctors 
welcomed initiatives that did not seem to cross the boundaries between the 
professions, they had more reservations about activities that did. Most importantly, 
however, is the question of how such services could be funded. The stakeholders 
identified two clear difficulties here: first, compensating pharmacists for possible loss 
of income from dispensing and second, providing adequate resources for locum cover. 
It was felt that compensation for loss of earnings from dispensing could come from the 
savings in the drugs bill generated by the pharmacists.  
 
Prioritisation 
A further important matter is that of which groups of patients should be targeted as a 
priority. It was not possible to relate the drug cost savings data to particular age 
groups. In terms of disease groups, savings were made mostly in relation to patients 
suffering from chronic respiratory problems, diabetes and dermatological complaints. 
There was general consensus amongst the stakeholders that any service would need to 
target patients on large numbers of repeat prescriptions, which generally refers to 
chronic patients and the elderly. There was also a feeling that patients starting off on a 
new drug would be an appropriate target group to see whether pharmacists could 
identify adverse drug reactions early.  None of the case studies in this report included 
patients starting on drug therapy.  However, there is a pilot ongoing that is looking at 
initiating patients on anti-depressant treatment. Moreover, in some areas, especially 




These pilots also raised the issue of cost effectiveness. There are a number of ways of 
thinking about cost/benefit implications. Potential costs include detrimental effects on 
patient health as a result of failure to take essential prescribed medication or side 
effects and an associated opportunity cost if patients visit their GP concerning these 
negative health outcomes. Any intervention on the part of the pharmacist, whether the 
outomes on patient health are positive or negative, involves an opportunity cost of 
time spent providing advice.  
Potential benefits include an improvement in patients’ health status as a result 
of regular monitoring and appropriate dispensing more closely matched to their health 
needs. Side effects could be avoided, reducing the need for patients to visit their GP, 
constituting an opportunity saving in GP time. Patients may be satisfied with the 
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system and gain more confidence in the pharmacist. They may then be more likely to 
seek advice from the pharmacist in future for symptoms that may have previously 
gone unreported or necessitated a GP consultation. A further important benefit is the 
reduction in wastage of dispensed medicines. This would result in few surplus drugs 
being stored at home thus reducing the possibility of accidents. An associated benefit 
is the financial saving corresponding to non-dispensed drug items.  
Cost effectiveness analysis and similar methods have been used in the 
economic calculation of a wide range of health care technologies and processes. They 
are applied with the intention of optimising the use of health care resources and 
arriving  at positions of first, allocation efficiency (the best allocation of resources 
between alternative uses for different purposes) and second, technical efficiency (the 
best [most efficient] choice between alternative technologies or processes aimed at the 
same objective). The rigorous application of economic evaluation techniques for 
comparative purposes requires carefully structured collection of costs and resource use 
data for all options being compared. These options can then be compared against a 
baseline position. Cost-effectiveness comparisons would use a common measure of 
outcomes (e.g. some indicator of physical patient health) to evaluate against changes 
in cost.  
This type of formal comparison was not possible in this project because local 
projects were already defined before the central evaluation team became involved. 
Consequently there was little consistency in the resource use and cost data that was 
collected and clear and objective outcome measures could not be established. 
Therefore the cost analysis is limited to measurement of costs, and, consideration of 
the scale and cause of changes can only be speculative. Nevertheless, as we have 
shown, there are grounds for thinking that these pilots had benefits for all the key 
stakeholders. There are indications that such services have the potential for preventing 
drug wastage and improving patients’ use of their medications. 
 The study demonstrates that community pharmacists have the enthusiasm and 
commitment to take on new roles. The challenge is how to make the most of this 
commitment and who should be responsible for facilitating changes in pharmacists’ 
roles. The new Primary Care Groups (PCGs) could take a part in this development. 
They do not have a role in managing the pharmacy contract nor access to the global 
sum so could not, for example, fund repeat dispensing via the national contract. 
However, they could pay for additional services such as prescribing advice. The study 
also raises the question of the role of the local health authorities and the Government. 
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APPENDIX: STAKEHOLDERS INTERVIEWED BY CHSS 
 
 






















Male, qualified 1979, 
proprietor 
 
Main road, surrounded 









Male, qualified 1980, 
proprietor 
 









Male, qualified 1970, 
employee 
 
Shopping area. Some 









Female, qualified 1992, 
manager 
 
Main road, residential 










Male, qualified 1984, 
proprietor 
 
Main road, residential 
area. Mostly deprived 









Male, qualified 1988, 
proprietor 
 
Main road, residential 





























Female, qualified 1959 
 
 
Central, surrounded by 








Group practice (2) 
 
Female, qualified 1972 
 
 








Group practice (3) 
 
 
Male, qualified 1983 
 
Central, retail and 












Female, qualified 1958 
 
Central, mainly well off 
  71 
 





























Village, health centre, 
not particularly well 







































Male, qualified 1969, 
locum 
 
Main road, shopping 










Male, qualified 1977, 
proprietor                 
 
 
Main road, both well 








mixture very well off 
and less well off 
 
 






















Group practice (3) 
 
 
Male, qualified 1964 
 
Housing area, small 








Group practice (7) 
 
 
Male, qualified 1966 
 
Main road, some shops, 
predominantly 
residential. Some very 








Group practice (9) 
 
 
Female, qualified 1986 
 
Main road surrounded 








Group practice (3) 
 
 
Female, qualified 1991 
 
Suburbs, mixed 
population, some very 








Group practice (9) 
 
Male, qualified 1985 
 
Main street, health 
centre, no deprivation 
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Table 5  RDS 2 PATIENT FOCUS GROUP* 
 
Patient Code Male/Female Age (approximately) 
1 Male Late 80s 
2 Male 60s 
3** Female Early 80s 
4** Female Late 70s/Early 80s 
 
*Jointly carried out by central evaluation team with local project manager 
 
**These patients did not contribute a lot to the discussion, although they did express agreement with the 
other patients’ views. In this respect there was a clear gender divide. It is important also to note that the 
results should be interpreted cautiously because of the small group size. 
 




























Residential and commercial 














Small town, residential and 
commercial; neither 






























Residential area, main road, 
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Male, qualified 1977 
 
On a dual-carriageway, very 









Group practice (2 ¾ ) 
 
Male, qualified 1984 
 
Residential area, neither 












Male, qualified 1975 
 
Residential area, about 45% 
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Village, deprived in the 



























Near motorway, high level 
of people on income 
support but some very 
high income areas too 
 
 





















Group practice (3 ½ ) 
 
 
Female, qualified 1972 
 
Village with small businesses 
and residential houses, not 











Male, qualified 1959 
 
Outside town centre, not very 









Group practice (2) 
 
Male, qualified 1977 
 
On a green, well off, 4% ethnic 
minorities 
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villages, not well off 













Main road, surrounded 
by residential houses, 










Male, qualified 1971, 
proprietor 
 
Large village, middle 













Main road outside 









































Group practice (2) 
 
 
Male, qualified 1958 
 








Group practice (3) 
 
 










Group practice (7) 
 
 
Male, qualified 1987 
 
Main road, residential 







Group practice (3) 
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Table 13 EAS 1 PATIENT FOCUS GROUP* 
 
Patient Code Male/Female Age  
1 Male 65 
2 Female 66 
3 Female 69 
4 Male 77 





*Jointly carried out by central evaluation team with local project manager 
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Female, qualified 1987, 
manager 
 














Small market town, high 
street, not particularly 













Just out of town, next to 














Attached to health 














Just outside city centre, 
suburbs, mixture of 







































Group practice (4) 
 
 
Male, qualified 1981 
 
Main street through 
village, residential area, 







Group practice (2) 
 
 
Male, qualified 1980 
 









Group practice (2) 
 
 
Male, qualified 1964 
 
Main road, residential 
and commercial, social 
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Group practice (3.5) 
 
 









Mixed: urban & rural 
 
Group practice (2) 
 
 
Male, qualified 1962 
 









Group practice (2) 
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